

Reversing Immunosenescence with Senolytics to Enhance Tumor

Immunotherapy

Niu Liu^{1,2,3#}, Jiaying Wu^{1,2#}, Enze Deng^{4,5#}, Jianglong Zhong^{1,2#}, Bin Wei^{1,2#}, Tingting Cai^{1,2#}, Xiaohui Duan⁶, Sha Fu⁷, David O. Osei-Hwedieh⁸, Ou Sha⁹, Yunsheng Chen^{1,2,3}, Xiaobin Lv¹⁰, Yingying Zhu¹¹, Lizao Zhang^{1,2}, Hsinyu Lin^{1,2}, Qunxing Li^{1,2}, Peichia Lu^{1,2}, Jiahao Miao^{1,2,3}, Teppei Yamada¹², Lei Cai¹³, Hongwei Du¹⁴, Sylvan C. Baca⁸, Qingpei Huang⁴, Soldano Ferrone[†], Xinhui Wang^{15*}, Fang Xu^{3,16,17*}, Xiaoying Fan^{4,18*}, Song Fan^{1,2*}

Affiliations:

¹Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital; Guangzhou, 510120, China.

²Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Guangzhou, 510120, China.

³Interdisciplinary Center for Brain Information, Brain Cognition and Brain Disease Institute, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences; Shenzhen, 518055, China.

⁴Guangzhou National Laboratory, Guangzhou International Bio Island; Guangzhou, 510005, China.

⁵MOE Key Laboratory of Gene Function and Regulation, Guangdong Province Key Laboratory of Pharmaceutical Functional Genes, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University; Guangzhou, 510275, China.

21 ⁶Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University;
22 Guangzhou, 510120, China.

23 ⁷Department of Cellular & Molecular Diagnostics Center, Sun Yat-Sen Memorial Hospital,
24 Sun Yat-Sen University; Guangzhou, 510120, China.

25 ⁸Department of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA, 02215, USA.

26 ⁹School of Dentistry, Shenzhen University Medical School; Shenzhen, 518037, China.

27 ¹⁰Jiangxi Key Laboratory of Oncology, The Third Affiliated Hospital, Jiangxi Medical
28 College, Nanchang University; Nanchang, 330008, China.

29 ¹¹Clinical Research Design Division, Clinical Research Center, Sun Yat-sen Memorial
30 Hospital, Sun Yat-sen University; Guangzhou, 510120, China.

31 ¹²Lecturer, Department of Gastroenterological Surgery, Faculty of Medicine, Fukuoka
32 University; Fukuoka, 814-0180, Japan.

33 ¹³Institute of Hepatopancreatobiliary Surgery, Chongqing General Hospital, Chongqing
34 University; Chongqing, 400038, China.

35 ¹⁴Cancer Institute, Xuzhou Medical University; Xuzhou, 221004, China.

36 ¹⁵Department of Surgery, Massachusetts General Hospital, Harvard Medical School; Boston,
37 02115, USA.

38 ¹⁶Faculty of Life and Health Sciences, Shenzhen University of Advanced Technology;
39 Shenzhen, 518107, China.

40 ¹⁷Shenzhen-Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced
41 Technology, Chinese Academy of Sciences; Shenzhen, 518055, China.

42 ¹⁸GMU-GIBH Joint School of Life Sciences, The Fifth Affiliated Hospital of Guangzhou
43 Medical University, Guangzhou Medical University; Guangzhou, 510005, China.

44 * Corresponding author. Email:

45 XWANG30@mgh.harvard.edu (X.W.); fang.xu@siat.ac.cn (F.X.);

46 fan_xiaoying@gzlab.ac.cn (X.F.); fansong2@mail.sysu.edu.cn (S.F.).

47 # These authors contributed equally to this work.

48 † Deceased 10 January 2023.

49

50 **Abstract: Recent advancements in cancer immunotherapy have improved patient**
51 **outcomes, yet responses to immunotherapy remain moderate. We conducted a Phase II**
52 **clinical trial (NCT04718415) involving 51 cancer patients undergoing neoadjuvant**
53 **chemoimmunotherapy and applied single-cell RNA and T/BCR sequencing on tumor and**
54 **blood samples to elucidate the immune cell perturbations. Our findings associate poor**
55 **response with reduced levels of CCR7⁺CD4 Naïve T cells and CD27⁺ Memory B cells, as**
56 **well as higher expression of immunosenescence-related genes in T and B cell subsets. Using**
57 **naturally aged and *Ercc1*^{+/-} transgenic aging mouse models, we found that senolytics**
58 **enhance the therapeutic efficacy of immunotherapy in multiple solid tumors by mitigating**
59 **tumor immunosenescence. Notably, we launched a Phase II clinical trial, COIS-01**
60 **(NCT05724329), which pioneers the combination of senolytics with anti-PD-1 therapy. The**
61 **clinical results demonstrate that this therapeutic strategy is associated with a favorable**
62 **safety profile and therapeutic efficacy, significantly mitigating adverse effects and**
63 **alleviating immunosenescence. These findings underscore the pivotal role of**

64 **immunosenescence characteristics in influencing the effectiveness of immunotherapy and**
65 **suggest a promising therapeutic efficacy along with a beneficial safety assessment for the**
66 **combination of senolytics with anti-PD-1 therapy.**

67

68 **Introduction:**

69 Despite recent advancements in blocking the PD-1/PD-L1 pathway, which have
70 revolutionized the treatment of solid tumors, only a small fraction of patients benefits from
71 immunotherapy, with fewer than 20% showing sustained responses¹⁻³. A major challenge in
72 current immunotherapy and neoadjuvant strategies is our limited understanding of the highly
73 dynamic and heterogeneous tumor immune microenvironment (TIME), which impacts treatment
74 responses⁴⁻⁶. The concept of cancer immunoediting emphasizes the immune system's dual role
75 in inhibiting tumor growth and shaping tumor immunogenicity. This process is described in three
76 stages: elimination, equilibrium, and escape. During the elimination phase, the host's innate and
77 adaptive immune systems recognize and respond to tumor-specific antigens^{7,8}. T cells are the
78 primary players in tumor immunity. Although tumor-reactive T cells are present in TIME, the
79 phenotypic heterogeneity of T cells across different tumors and their divergent differentiation
80 fates remain significant. Exhaustion still poses a major limitation to their anti-tumor potential
81^{9,10}.

82 Immunosenescence, a well-established phenomenon occurring with age, results in the
83 immune system losing its ability to effectively respond to pathogens and cancer cells¹¹⁻¹⁵.
84 Recent studies have uncovered the complex role of immunosenescence in tumors, with factors
85 such as cAMP, glucose competition, and oncogenic stress in the TIME inducing senescence in T
86 cells, macrophages, natural killer (NK) cells, and dendritic cells, thereby impairing their immune

87 cytotoxic function against tumors¹⁶. However, it remains unclear whether individual differences
88 in immunosenescence affect the efficacy of immunotherapy in cancer patients.

89 Previous studies have shown that blocking DNA damage signals can inhibit the senescence of
90 tumor-infiltrating T cells, thereby enhancing the efficacy of immune checkpoint inhibitors (ICIs)
91 against tumors¹⁷. Recent research also indicate that chronic inflammation caused by an aging
92 immune system can promote cancer development, regardless of the age of the cancerous or
93 surrounding tissues¹⁸. Therefore, we believe that the senescence status of immune cell
94 subpopulations, which play a crucial role in tumor immunity, may be critical for treatment
95 outcomes. We hypothesize that senolytics can be combined with ICIs to enhance their efficacy in
96 treating solid tumors.

97 In this study, we first explored the variability in patient responses to neoadjuvant
98 immunotherapy, starting with a Phase II clinical trial in head and neck squamous cell carcinoma
99 (HNSCC, NCT04718415). Further analysis of single-cell RNA sequencing (scRNA-Seq) data
100 from these patients allowed us to identify key immune cell subpopulations that influence
101 immune responses and to reveal the negative impact of immunosenescence on immunotherapy
102 efficacy. Additionally, animal study data highlighted the potential benefits of combining
103 senolytics with ICIs for treating solid tumors, including HNSCC, bladder cancer, and breast
104 cancer. We then initiated a pioneering Phase II clinical trial (COIS-01, NCT05724329) to
105 evaluate the efficacy and safety of combining anti-aging drugs with ICIs in HNSCC patients.
106 Our results indicate that the neoadjuvant combination of senolytics and ICIs significantly reduces
107 toxic side effects compared to neoadjuvant chemotherapy. Furthermore, patients receiving the
108 combination therapy exhibited a higher proportion of CCR7⁺ naïve T cells within their tumors,
109 suggesting a mitigation of immunosenescence and an enhancement of the adaptive immune
110 response.

111

112 **Results:**

113 **Phase II trial evaluating neoadjuvant chemotherapy combined with immunotherapy for**
114 **oral cavity and oropharyngeal squamous cell carcinoma (OOC-001)**

115 We enrolled 51 patients with stage II-IVA HNSCC for neoadjuvant chemoimmunotherapy
116 (OOC-001, NCT04718415). One patient was excluded from the evaluation due to refusing to
117 continue the treatment (Extended Data Fig. 1a). All patients underwent a minimum of two cycles
118 of neoadjuvant treatment, with 24 (47.1%) receiving 2 cycles, 23 (45.1%) receiving 3 cycles, and
119 4 (7.8%) receiving 4 cycles of neoadjuvant treatment (Tables 1-2 and Supplementary Tables 1-2).
120 Among the 48 evaluable patients, 23 patients achieved pathological complete response (pCR,
121 47.9%), 8 patients achieved major pathological response (MPR, 16.7%), 10 patients showed
122 partial pathological response (pPR, 20.8%), and 7 patients displayed pathological no response
123 (pNR, 14.6%) (Fig. 1a, Extended Data Fig. 1b). The comparison of radiologic and pathologic
124 response indicators suggested that certain patients were pathologically assessed as pCR while
125 radiologically assessed as PR (Partial response)/SD (Stable disease), highlighting significant
126 inconsistency between pathological and radiological assessments (Fig. 1b). Compared to the
127 baseline, 72.7% of primary tumors exhibited shrinkage, while only 46.7% of patients showed
128 regression in lymph nodes, possibly indicating that primary tumors in HNSCC are more sensitive
129 to neoadjuvant therapy (Fig. 1c and Extended Data Fig. 1c-e). Regarding treatment cycles,
130 pathological assessment suggested that the efficacy of the 2-cycle treatment might be less than
131 that of 3 or 4 cycles (Extended Data Fig. 1f). 48 patients (94%) experienced at least one
132 treatment-related adverse effect (TRAE). Grade 3-4 TRAEs were observed in 26 patients (51%),

133 and the most common TRAEs were alopecia (75%), asthenia or fatigue (53%), and nausea (49%)
134 (Table 2).

135 The 24-month overall survival (OS) for the cohort was 93.9% (Extended Data Fig. 1g, h).
136 Our findings show that combining sintilimab with carboplatin and nab-paclitaxel resulted in
137 manageable side effects and achieved a high overall response rate (64.6%, MPR and pCR).
138 Considering the trade-off between anti-tumor effectiveness and adverse effects, we observed that
139 a 3-cycle treatment regimen offered superior benefits for patients with HNSCC.

140 **Immune landscape of HNSCC patients with neoadjuvant chemoimmunotherapy**

141 scRNA-Seq and scT/BCR-Seq was performed in seven treatment-naïve tumor samples and
142 nine blood samples (including pre-and post-treatment) (Fig. 1d, Supplementary Table 1).
143 Following quality filtering, we obtained scRNA-Seq profiles as well as TCR and BCR
144 clonotypes from 143,056 cells, encompassing T cells, NK cells, B cells, myeloid cells,
145 fibroblasts, endothelium, and tumor cells (Supplementary Figure 1a-f). A total of 27 cell clusters
146 with distinct molecular features were observed by re-clustering each major immune cell type
147 (Fig. 1e).

148 We analyzed the abundance of various immune subtypes and compared their proportions
149 across the tumor, pre-treatment blood (P0) and post-treatment blood (P1) of MPR and noMPR
150 patients. The proportion of CD4⁺ T cells showed the largest elevation among all immune cell
151 types when comparing P1 to P0 (Supplementary Figure 1g, h). While compared to noMPR
152 patients, MPR patients' tumors exhibited higher proportions of CCR7⁺CD4 Naïve T cells,
153 CXCL13⁺CD4 T cells, GZMK⁺CD8 Tem cells, and CD27⁺ Memory B cells. Conversely, the
154 proportions of FOXP3⁺CD4 Treg cells and IGF1⁺ macrophages (IGF1⁺ Mφ) were lower (Fig. 1f
155 and Supplementary Figure 2, 3a-f). The upregulated genes in noMPR patients of the main T/B

156 cell subtypes were involved in aging-related pathways, indicating these pathways may contribute
157 to variations in the treatment response status of HNSCC patients. (Supplementary Figure 3g,
158 Supplementary Table 3). Using T/BCR diversity as markers of antigenic immune responses to
159 neoadjuvant therapy, we investigated TCR and BCR clonality in MPR and noMPR groups
160 through three different methods (Chao1, Shannon Index, and Richness). The results showed that
161 MPR patients exhibited higher TCR and BCR clonal diversity in $CCR7^+CD4$ Naïve T cells,
162 $CXCL13^+CD4$ T cells, $GZMK^+CD8$ Tem cells, and $CD27^+$ Memory B cells (Fig. 1g and
163 Supplementary Figure 3h). Additionally, dominant clones present in the tumor and blood before
164 treatment persisted as the dominant clones after treatment in MPR patients (Extended Data Fig.
165 2a-c). Further analysis of TCR/BCR clonotypes from P0, P1, and tumors revealed no significant
166 differences in TCR/BCR clonotypes in blood before and after treatment, nor between MPR and
167 noMPR patients. Interestingly, MPR patients exhibited a greater number of unique TCR/BCR
168 clonotypes within tumors, suggesting a richer TCR/BCR clonal diversity (Extended Data Fig. 2d,
169 e).

170 Immunosenescence refers to the decline in the immune system's ability to effectively
171 respond to pathogens and cancer cells¹¹. Recent studies have found that characteristics of
172 immunosenescence include an imbalance in the proportion of naïve and memory T cells, a
173 decrease in the number of TCR clones, and elevated levels of $p16^{INK4a}$ (also known as $CDKN2A$)
174 and $p21^{CIP1}$ ($CDKN1A$) expression^{19,20}. We then examined the expressions of the senescent
175 markers, P16 and P21, by immunostaining in tumor tissues from two clinical trials conducted at
176 our center (OOC-001 and REDUCTION-I, NCT05582265). The results revealed that the tumor
177 microenvironment of noMPR patients exhibited higher levels of senescent features (Fig. 1h and
178 Extended Data Fig. 2f). In summary, our data suggests that non-responsive patients to

179 neoadjuvant treatment demonstrate dysregulation in immune cell proportions and an increase in
180 senescent characteristics.

181 **T cell and B cell subtypes exhibiting senescent features influence the response to** 182 **immunotherapy**

183 Recent studies have shown that in late life, the aging individual's adaptive immune system
184 exhibits dysfunction and increased autoimmunity, with T and B cell aging being a primary
185 manifestation of immunosenescence^{21,22}. However, there is no gold standard marker for defining
186 the senescence of T and B cells²³. To figure out this assumption, we first created an
187 immunosenescence-associated gene set (IAGs) consists of 154 genes based on extensive scRNA-
188 Seq datasets differentiating immune cells from young and elderly individuals (Extended Data Fig.
189 3a, Supplementary Table 4). The IAGs were significantly enriched in the immune cells of elderly
190 individuals in three independent scRNA-Seq datasets (GSE157007²⁴, GSE141595²⁵ and
191 PRJCA002856) (Fig. 2a and Extended Data Fig. 3b-d), indicating they could reflect human
192 immunosenescence characteristics. Additionally, evaluating IAGs in scRNA-Seq datasets for
193 HNSCC and triple-negative breast cancer (TNBC)²⁶ immunotherapies also revealed lower
194 senescent scores in MPR patients compared to noMPR patients (Extended Data Fig. 3e).
195 Subsequently, we used IAGs to score T cells and their subtypes, which revealed lower
196 immunosenescence features in MPR patients with HNSCC (Fig. 2b and Extended Data Fig. 4a).
197 Furthermore, we also identified senescent genes associated with T cells from the IAGs, which
198 showed higher expression levels in multiple T cell subgroups of noMPR patients, with GO
199 analysis revealed enrichment in pathways related to S100 protein binding (Fig. 2c and Extended
200 Data Fig. 4b, c). Similar results were obtained from the TNBC dataset (Extended Data Fig. 4d-h).

201 Relative to noMPR patients, MPR patients exhibited lower $V\alpha/\beta$ gene usage frequencies in
202 $CCR7^+CD4$ T cells and $FOXP3^+CD4$ Treg cells in both tumors and blood, consistent with
203 previous findings (Extended Data Fig. 5a). Pseudotime analysis of immune cells revealed that
204 $CD4^+$ T cell subsets in peripheral blood exhibit an early differentiation phenotype, while their
205 tumor counterparts show a more differentiated phenotype. Notably, MPR patients demonstrated
206 differentiation towards $CCR7^+CD4$ Naïve T cells and $CXCL13^+CD4$ Th cells, maintaining T cell
207 vitality and the potential to differentiate into various functional subtypes. In contrast, $CD4^+$ T
208 cells in non-MPR patients tended to differentiate towards $FOXP3^+CD4$ Tregs, leading to
209 immunosenescence-related characteristics (Extended Data Fig. 5b-d).

210 Numerous T cells demonstrate shared clonotypes between tumors and blood. These clonal T
211 cells in tumor showed elevated IAGs scores than those in blood, suggesting a higher level of
212 senescent characteristics for the tumor-infiltrating T cells (Fig. 2d, e). Analysis of paired TCR
213 data revealed a notable reduction of both unique and total clonotypes particularly in the
214 $CCR7^+CD4$ Naïve T cells in noMPR patients compared with MPR patients (Fig. 2f).
215 Immunosenescence features are notably pronounced in B cells of noMPR patients, particularly in
216 $CD27^+$ Memory B cells (Extended Data Fig. 6a-e). Pairwise analysis of T and B cell receptors
217 and ligands revealed strong interactions between $FOXP3^+CD4$ Treg cells and $CXCL13^+CD4$ T
218 helper cells with B cells (Extended Data Fig. 6f). This indicates that in MPR patients, the
219 reduced number of $FOXP3^+CD4$ Tregs and increased number of $CXCL13^+CD4$ T helpers may
220 exert their effects through interactions with B cells.

221 Through immunofluorescence staining, we confirmed that $CD4^+$ T cells and $CD27^+$
222 memory B cells expressing the senescent marker S100A11 were more abundant in noMPR
223 patients, while no difference was observed in the number of $S100A11^+CD8$ T cells between
224 noMPR and MPR patients, suggesting senescent status of $CD4$ T cells critically modulate

225 patients' response to neoadjuvant therapy (Fig. 2g and Extended Data Fig. 6g). Analysis of
226 HNSCC Patients' data from the TCGA database found that patients with high expression of IAGs
227 such as *S100A11*, *AREG*, *CALD1*, *CDKN1A*, and *CASP4* together with low CD4 Naïve T cell or
228 memory B cell abundance had significantly worse prognosis than those with low expression of
229 senescent genes and high proportions of CD4 Naïve T cells or memory B cells (Fig. 2h and
230 Supplementary Figure 4). T cells predict responses to immunotherapy more effectively in
231 HNSCC patients, while in TNBC patients, B cells are more predictive (Fig. 2i). These analyses
232 suggest that the IAGs we constructed were effective in distinguishing the immune cells of
233 noMPR and MPR patients, and that lower expression levels of IAGs in CCR7⁺CD4 Naïve T and
234 CD27⁺ Memory B cells are associated with a positive treatment response.

235 **IGF1⁺ Mφ induce senescent characteristics in T cells**

236 Innate immune cells play an important role in early tumor cell recognition and subsequent
237 initiation of inflammation and antitumor responses. To investigate whether non-lymphocyte
238 immune cells are involved in the immunosenescence phenotype observed in our study subjects,
239 we analyzed the gene expression features of myeloid cells. IGF1⁺ Mφ exhibited the highest
240 differentiation score among all myeloid cell types according to pseudotime analysis (Extended
241 Data Fig. 7a). The precursor cells of IGF1⁺ Mφ in the blood are IL1B-CD14 cells, which showed
242 significant changes in the MPR group before and after treatment. Interestingly, the proportion of
243 IGF1⁺ Mφ within tumors and IL1B-CD14 cells in blood were significantly higher in noMPR
244 patients (Fig. 2j and Extended Data Fig. 7b-d). Additionally, IGF1⁺ Mφ negatively correlated
245 with CCR7⁺CD4 Naïve T cells and CD27⁺ Memory B cells in tumors (Fig. 2k). We also
246 examined the composition proportions of myeloid cell subtypes in TNBC patients and found that
247 PR patients had a higher proportion of IGF1⁺ Mφ compared to SD patients, consistent with our
248 HNSCC results (Extended Data Fig. 7e, f). By scoring the expression of six major senescence-

249 associated secretory phenotype (SASP) factors in HNSCC and TNBC, we found that IL1B-
250 CD14 monocytes and IGF1⁺ M ϕ expressed higher levels of SASP factors compared to other
251 myeloid cell subtypes (Extended Data Fig. 7g, h). Interaction analysis further revealed that
252 IGF1⁺ M ϕ had a strong potential for interaction with T cells (Supplementary Figure 5a-c).
253 Enrichment analysis of pathways related to IGF1⁺ M ϕ and IL1B-CD14 cells revealed
254 involvement in senescent and inflammatory pathways, including ERK, MAPK and IL-1
255 pathways. Consequently, IGF1⁺ M ϕ in the TIME may induce immunosenescence in T cells.
256 Analysis of TCGA data for HNSCC patients demonstrated that those with high IGF1 signature
257 had relatively poor OS and progression-free survival (PFS) (Extended Data Fig. 7i and
258 Supplementary Figure 5d, e). In conclusion, our analysis of myeloid cell subtypes suggests that
259 IGF1⁺ M ϕ could be a crucial factor contributing to the limited response of tumor patients to
260 immunotherapy. These cells may trigger an immunosenescent status in the TIME through their
261 interactions with T cells.

262 **Senolytics combined α PD-1 alleviate TIME senescent burden in HNSCC**

263 Currently, the role of the senescent phenotype in HNSCC and its interaction with tumor
264 cells, immune cells, or other cell types remains poorly understood. The impact of senolytics
265 treatments or their combination with other therapies in HNSCC is yet to be determined.
266 Histochemical staining with β -galactosidase revealed a significantly more pronounced senescent
267 phenotype in HNSCC tissue compared to the adjacent normal tissue (Fig. 3a). Then, we
268 established a 4-NQO-induced (4-Nitroquinoline-N-oxide) HNSCC mouse model using 12-
269 month-old C57BL/6 (C57) mice (Fig. 3b). The mice underwent the typical progression of normal
270 epithelium-epithelial dysplasia-invasive cancer, with an average age of tumor occurrence around
271 20 months, reflecting the real progression of HNSCC in elderly patients more accurately
272 (Extended Data Fig. 8a). Immunofluorescence staining on tumor sections confirmed significantly

273 higher expression of the key senescent marker P16 in the tumor region compared to surrounding
274 normal tissue (Fig. 3c).

275 To further investigate the effect of senolytics on HNSCC, we randomly divided the 4-NQO-
276 induced tumor mice into four groups, administering Isotype, α PD-1 (anti PD-1), α PD-1+CP (anti
277 PD-1+Cisplatin), or α PD-1+DQ (anti PD-1+Dasatinib+Quercetin) treatments (Fig. 3b). The
278 α PD-1+DQ group exhibited fewer lesions compared to other groups. Interestingly, there was no
279 significant difference between the α PD-1 group and the α PD-1+CP group (Fig. 3d and Extended
280 Data Fig. 8b) while α PD-1+DQ group had a longer lifespan compared to other groups (Fig. 3e
281 and Extended Data Fig. 8c). Moreover, flow cytometry revealed that α PD-1+DQ treatment
282 effectively decreased β -galactosidase expression in CD45⁺ immune cells within tumors (Fig. 3f).
283 Correlation analysis further demonstrated a negative relationship between mice survival time and
284 β -galactosidase expression in immune cells, confirming the anti-tumor effect of α PD-1+DQ by
285 reversing immunosenescence in HNSCC mice (Fig. 3g).

286 Subsequently, we evaluated changes in CD4⁺, CD8⁺, and B220⁺ cells in the spleen, blood,
287 bone marrow, and tumors across different treatment groups using flow cytometry. The α PD-
288 1+DQ group showed an increased proportion of CD4⁺ cells within tumors, while CD8⁺ and
289 B220⁺ cell levels exhibited no significant differences compared to other groups (Fig. 3h). Similar
290 results were observed in the spleen (Extended Data Fig. 8d, e). However, B220⁺ cell counts were
291 relatively elevated in peripheral blood samples from the α PD-1+DQ group (Extended Data Fig.
292 8f-g). Additionally, the expression levels of *p16* and *p21* were significantly reduced in tumor-
293 infiltrating CD4⁺ cells from the α PD-1+DQ group (Fig. 3i), whereas no significant differences
294 were noted in CD8⁺ cells (Extended Data Fig. 8h). Furthermore, an increased proportion of
295 CD62L⁺CD44⁻ naïve CD4⁺ cells was observed in the α PD-1+DQ group (Fig. 3j).
296 Immunofluorescence staining consistently confirmed a significant increase in CD4⁺CD62L⁺ cells

297 in the α PD-1+DQ group relative to the other groups (Fig. 3k and Supplementary Figure 6).
298 Together, these findings suggest that immunosenescence in HNSCC surpasses that in
299 surrounding normal tissue, and the combination of α PD-1+DQ may enhance the therapeutic
300 efficacy of α PD-1 by mitigating the senescent phenotype of tumor immune cells, particularly in
301 CD4⁺ cells.

302 **Synergistic reduction of SASP and increase in CD4⁺ Naïve T cells by senolytics and α PD-1** 303 **in solid tumors**

304 To determine the effectiveness of α PD-1+DQ in various transplant tumor models, including
305 HNSCC, we established two mouse oral squamous cell carcinoma cell lines, 4N-MS1 and 4N-
306 MS2, from the 4-NQO model (Fig. 4a, Extended Data Fig. 9a, b). To simulate the systemic
307 senescence in normal elderly mice, we used *Ercc1*^{+/-} mice, which exhibit rapid senescent
308 characteristics such as hair loss and graying like 20-month-old wild-type mice by the age of 10
309 months (Fig. 4b). Further measurements of spleen weight and 8-hydroxy-2-deoxyguanosine (8-
310 OHdG) content in the spleen showed that *Ercc1*^{+/-} 10m mice had similar 8-OHdG levels and
311 spleen weight as WT 20m mice. Immunofluorescence staining revealed that 10-month-old
312 *Ercc1*^{+/-} mice expressed more γ H2AX in the spleen, heart, liver, and lungs compared to wild-
313 type mice (Fig. 4c-e). In summary, *Ercc1*^{+/-} 10m mice exhibited senescent characteristics like
314 naturally aging wild-type mice.

315 We implanted 4N-MS1 cells into the tongues of 10-month-old *Ercc1*^{+/-} mice and, on the 5th
316 day, treated the mice with Isotype, α PD-1, α PD-1+CP, or α PD-1+DQ (Fig. 4f). Tumor growth
317 curves showed that mice in the α PD-1+DQ group had better treatment outcomes than other
318 groups (Fig. 4g). Additionally, we employed the Multiplex bead-based protein analysis method
319 to measure the expression of various SASP factors in tumor tissue lysates. The results revealed

320 that α PD-1+DQ treatment significantly reduced the expression of various SASP factors within
321 the tumor, including IL-2, TNF- α , IFN- γ , IL-10, CCL20, MCP-3, and others (Fig. 4h and
322 Supplementary Table 5). Furthermore, flow cytometric analysis showed an increase in
323 CD62L⁺CD44⁻CD4⁺ Naïve cells in the α PD-1+DQ group compared to the Isotype group (Fig. 4i).
324 Consistently, immunofluorescence staining confirmed a significant decrease of P21⁺ cells in the
325 α PD-1+DQ group compared to the other three groups (Fig. 4j). Moreover, we implanted MB49
326 (bladder cancer) and E0771 (breast cancer) tumors subcutaneously in 10-month-old *Ercc1*^{+/-}
327 mice and observed therapeutic outcomes like those seen with the 4N-MS1 transplant model. (Fig.
328 4k and Extended Data Fig. 9c-f). In summary, these data suggest that α PD-1+DQ treatment can
329 suppress tumor growth in multiple solid tumors while enhancing immune microenvironment
330 vitality through reduced SASP and increased CD4⁺ Naïve cells.

331 **Senolytics reduce senescent characteristics and enhance activation of tumor-infiltrating** 332 **CD4⁺ Naïve T cells**

333 To investigate the unique functionality of significantly increased CD4⁺CD62L⁺ Naïve T
334 cells in tumors after combined α PD-1+DQ therapy in anti-tumor immunity, we isolated
335 CD62L⁺CD44⁻CD4⁺ cells from tumors of mice treated with Isotype, α PD-1, or α PD-1+DQ, and
336 performed RNA-Seq and ATAC-Seq (Fig. 5a). The results of RNA-Seq showed that, compared
337 to Isotype or α PD-1 treatment, the α PD-1+DQ group exhibited significantly higher expression of
338 genes related to T-cell migration (*Ccr7*) or antigen response (*Lck*, *Cfd*) in Naïve T cells (Fig. 5b,
339 Extended Data Fig. 10a and Supplementary Table 6). GO analysis revealed enrichment in
340 pathways related to T-cell maintenance, differentiation, and antigen presentation for both α PD-
341 1+DQ and Isotype groups, indicating that the combination of senolytics with α PD-1 may
342 enhance immune response levels by promoting proliferation and differentiation of Naïve T cells
343 (Fig. 5c and Extended Data Fig. 10b). Additionally, ATAC-Seq analysis demonstrated that,

344 relative to Isotype or α PD-1 treatment, the α PD-1+DQ group exhibited significantly higher
345 chromatin accessibility of the *Ccr7* gene, crucial for adaptive immune responses. Conversely,
346 genes associated with immunosenescence and chronic inflammation, such as *S100a11*, showed
347 lower chromatin accessibility (Fig. 5d, Extended Data Fig. 10c-g and Supplementary Table 7).
348 Furthermore, joint GO analysis of RNA-Seq and ATAC-Seq results from the α PD-1+DQ and
349 Isotype groups yielded similar findings (Fig. 5e). qPCR measurements confirmed that α PD-
350 1+DQ treatment upregulated genes associated with T cell activation, such as *Ccr7*, *Lck*, and *Cfd*,
351 and downregulated genes linked to immunosenescence, including *p16*, *p21*, and *S100a11*, in
352 tumor-infiltrating CD4⁺ Naïve T cells. (Fig. 5f). Additionally, flow cytometry and
353 immunofluorescence staining also demonstrated a significant increase in CCR7 and LCK-
354 positive CD4⁺ Naïve T cells following α PD-1+DQ treatment (Fig. 5g, h). In conclusion, our
355 results indicate that α PD-1+DQ treatment effectively reduces the senescent phenotype while
356 markedly enhancing the quantity and differentiation potential of tumor-infiltrating CD4⁺ Naïve T
357 cells.

358 **Combination of anti-PD-1 with dasatinib and quercetin demonstrates safety and efficacy in** 359 **patients with HNSCC.**

360 Previous studies have indicated that neoadjuvant chemotherapy reduces recurrence in
361 patients with locally advanced oral cancer but does not improve survival rates^{27,28}. Recent
362 research indicates that chemotherapy can exacerbate the adverse effects associated with
363 immunotherapy. The most prevalent adverse effects of neoadjuvant immunochemotherapy
364 include alopecia (100.0%), nausea/vomiting (60.4%), and fatigue (50.0%)²⁹. Therefore, it is
365 essential to investigate novel therapeutic agents that can enhance the efficacy of immunotherapy
366 while minimizing systemic side effects, preserving the function of vital organs, and ultimately
367 improving the quality of life for patients.

368 Based on our findings from single-cell multi-omics analysis and animal models, we
369 hypothesized that combining ICIs with dasatinib and quercetin would be both effective and safe
370 for patients with HNSCC, significantly reducing TRAEs compared to standard neoadjuvant
371 chemotherapy. To evaluate this hypothesis, we conducted a prospective, open-label, single-
372 center, Phase II clinical trial (COIS-01), assessing the neoadjuvant efficacy of tislelizumab
373 combined with dasatinib and quercetin in resectable HNSCC patients. The primary endpoint of
374 the study was the MPR rate (Fig. 6a). Between February 5, 2023, and April 5, 2024, a total of 24
375 patients were enrolled according to the study protocol. Efficacy evaluations revealed that 4
376 patients (16.7%) achieved a pCR, while another 4 (16.7%) achieved a MPR, resulting in an
377 overall treatment response rate of 33.3% (pCR + MPR) (Fig. 6b, Table 3 and Supplementary
378 Table 8). Representative imaging, pathological assessments, and clinical photographs of patients
379 achieving pCR are provided (Fig. 6c).

380 Safety analyses of the 24 patients demonstrated that only 1 patient experienced grade 3-4
381 TRAEs (Fig. 6d). In contrast, the OOC-001 trial, which evaluated neoadjuvant chemotherapy,
382 showed the most common TRAEs were alopecia (75%), asthenia or fatigue (53%), and nausea
383 (49%) (Fig. 6e, Table 2). In the COIS-01 trial, the corresponding incidences were notably lower,
384 with 0% for alopecia, 25% for asthenia or fatigue, and 16.7% for nausea (Table 4 and
385 Supplementary Table 9). Although the survival period in COIS-01 has not yet allowed for
386 statistical analysis of overall survival, no recurrences or deaths have been observed to date.
387 Furthermore, immunohistochemical analysis of patient paraffin sections before and after α PD-1
388 + DQ treatment revealed an upregulation of CCR7 expression in naïve T cells post-treatment
389 (Fig. 6f). These early findings from the COIS-01 trial suggest that the combination of
390 tislelizumab with dasatinib and quercetin demonstrates promising antitumor efficacy, favorable
391 tolerability, and a potential to mitigate immunosenescence-related features.

392

393 **Discussion**

394 The central conclusion of this study is that the senescence of TIME is a critical factor
395 affecting the efficacy of tumor immunotherapy. The first evidence supporting this conclusion
396 comes from the multidimensional single-cell data analysis of immune cells from both blood and
397 tumors of patients in clinical trials. We observed that noMPR patients exhibited more
398 pronounced immunosenescence features, including a decreased proportion of naïve T cells and
399 memory B cells, an increased proportion of immunosuppressive cell subtypes, and a reduction in
400 the TCR/BCR repertoire. Additionally, we identified IAGs in immune cells from noMPR
401 patients, which showed higher expression levels across various T and B cell subsets. When
402 tumor-bearing mice received a combination of ICI and senolytics, we observed an increase in
403 CD4⁺ naïve T cells and a reduction in senescence markers in immune cells within the tumors.
404 This led to reduced tumor burden and extended survival in the mice. A clinical trial based on our
405 findings further confirmed the potential advantage of combining ICI with senolytics for treating
406 solid tumors.

407 Immune cells are the cornerstone of tumor immunotherapy^{30,31}. T cell-centered therapies
408 have become powerful tools against cancer. ICI is the most widely used immunotherapy method
409 for solid malignancies, with an increasing number of monoclonal antibodies targeting different
410 inhibitory receptors entering clinical practice³². Antibodies against PD-1, CTLA-4, and LAG-3
411 have been FDA-approved for several types of solid tumors. Although ICI can induce objective
412 responses even in the challenging context of metastatic disease, only a minority of patients
413 (estimated at <30%) achieve sustained and/or complete clinical responses³³⁻³⁵. The TIME is rich
414 in tumor-reactive T cells, but exhaustion remains a major factor limiting their antitumor

415 capabilities. Studies on chronic antigen stimulation models in mice^{36–38} and the characteristics of
416 tumor-infiltrating lymphocytes (TILs) in human "hot" tumors^{39–41} emphasize that antitumor T
417 cells can progressively acquire a dysfunctional state, allowing tumor immune evasion^{42,43}. These
418 findings suggest that the TIME is not isolated but interconnected with the systemic immune
419 system. The dynamic processes of TILs dysfunction and continuous recruitment of immune cells
420 to the tumor provide a new perspective for exploring ways to improve the TIME during tumor
421 progression.

422 Notably, our study shows no significant differences in the proportions of most immune cell
423 types in the peripheral blood of responsive and non-responsive patients before and after
424 treatment. This indicates that predicting immunotherapy responses based on peripheral blood
425 tests may be challenging. Although cellular senescence drives various age-related complications
426 through SASP, identifying senescent immune cells in vivo remains difficult^{44–46}. Recent studies
427 have identified a set of genes (SenMayo) enriched in bone biopsies from elderly individuals,
428 capable of identifying senescent hematopoietic or stromal cells at the single-cell level in human
429 and mouse bone marrow/bone scRNA-Seq data⁴⁶. Researchers also established AgeAnno, a
430 human aging single-cell annotation knowledge base, offering dynamic functional annotations of
431 1,678,610 cells from 28 healthy tissue samples⁴⁷. Currently, there are no specific markers or
432 gene sets dedicated to reflecting the degree of immunosenescence. We have constructed an
433 immunosenescence-related gene set comprising 154 genes (IAGs), which has effectively
434 distinguished between young and elderly individuals in external datasets. This provides a
435 powerful tool for future research on the senescent status of the immune system. It is important to
436 note that the immune system consists of diverse cell types, each with distinct functions. For
437 example, the gene expression profiles of senescent states in T cells, dendritic cells, and

438 macrophages may differ significantly. Understanding these differences is crucial for developing
439 targeted therapies for senescent phenotypes.

440 Senolytics therapies for various cancers are currently under investigation. Studies have
441 shown that senolytics ABT-263 can exert antitumor effects by selectively clearing senescent
442 cells in obese patients' tumor tissues⁴⁸. Additionally, the plant compound Rutin, when combined
443 with chemotherapy, can intervene in tumor development⁴⁹. These studies suggest that senolytics
444 may offer unique advantages in cancer treatment, with fewer side effects and promoting overall
445 systemic health. However, the combination of senolytics and ICI has not been explored in TIME.
446 Previous research discussed the potential benefits of DQ therapy, a novel senolytics regimen that
447 disrupts survival pathways of senescent cells and selectively targets them⁵⁰⁻⁵². Recent research
448 on systemic administration of DQ for treating intervertebral disc degeneration has provided new
449 insights, highlighting the tissue-specific effects of DQ and the importance of treatment timing⁵³.
450 Additionally, a clinical trial on DQ treatment for idiopathic pulmonary fibrosis (IPF)
451 demonstrated significant improvements in patients' physical function^{54,55}. Our COIS-01 trial has
452 demonstrated the efficacy and safety of combining senolytics with ICIs in HNSCC patients.
453 Previous studies have shown that ICIs monotherapy in HNSCC has limited effectiveness, with
454 reported MPR rates of 7-13.9%⁵⁶⁻⁵⁸. In contrast, the COIS-01 trial achieved an MPR rate of
455 33.3%. While immunochemotherapy can achieve higher MPR rates, it is associated with
456 significant toxicity, with grade ≥ 3 adverse events occurring in up to 35% of patients⁵⁹,
457 substantially higher than in the COIS-01 trial, where the incidence of such events was
458 considerably lower (4.2%). Grade ≥ 3 toxicities can severely impact patient quality of life and
459 pose challenges for subsequent adjuvant immunotherapy. Discontinuation of adjuvant

460 immunotherapy due to toxicity may compromise the overall therapeutic efficacy, potentially
461 affecting survival outcomes⁶⁰.

462 Given this balance between efficacy and risk, the COIS-01 trial offers a novel therapeutic
463 strategy that maximizes the antitumor efficacy of ICIs while minimizing adverse events.
464 Preclinical studies in multiple mouse models have demonstrated the superior potential for long-
465 term survival with the combination of α PD-1 and senolytics (dasatinib and quercetin) compared
466 to monoimmunotherapy or immunochemotherapy. Consistently, the combination of senolytics
467 and anti-PD-1 therapy has been shown to dramatically upregulate CCR7⁺ naïve T cells in COIS-
468 01 patients, a critical feature in the modulation of immunosenescence⁶¹. This upregulation
469 enhances the homing⁶², immune surveillance⁶³, and circulating maintenance⁶⁴ of these specific
470 T cells, potentially predicting improved survival outcomes in clinical settings. However, rigorous
471 randomized clinical trials are needed to further validate these findings. Additionally, further
472 investigation is required to determine the optimal type and dosage of senolytics in combination
473 with ICIs. In summary, this study provides valuable insights into the variability of TIME across
474 individuals and highlights the potential to enhance antitumor efficacy by targeting
475 immunosenescence.

476

477 **Acknowledgments:** We thank all patients and their families for participation during sample
478 collection. We are grateful to the support of the Clinical Research Design Division and Clinical
479 Research Center at Sun Yat-sen Memorial Hospital, Sun Yat-sen University. The co-author Dr.
480 Soldano Ferrone sadly passed away on January 10, 2023, at the age of 82, after an 8-week-long
481 battle with COVID-19. He was the supervisor of Dr. Song Fan during Dr. Fan's post-doctoral
482 work in his lab at Massachusetts General Hospital (MGH). Due to his constantly invaluable

483 guidance and suggestions, which greatly helped improve and organize this study, all contributing
484 authors agree to keep him as a co-author of this manuscript. We thank all the members of the Fan
485 lab for valuable discussions and help with experimental techniques and analysis of the
486 manuscript. This work was supported by the Joint Funds of the National Natural Science
487 Foundation of China (U21A20381), the General Funds of the National Natural Science
488 Foundation of China (82373452), the Guangdong Natural Science Funds for Distinguished
489 Young Scholar (2022B1515020061), the Guangdong Basic and Applied Basic Research
490 Foundation (2021A1515220138), the Guangzhou Basic Research Program Jointly Funded by
491 Municipal Schools (Institutes) (202201020367), the Fundamental Research Funds for the Central
492 Universities, Sun Yat-sen University (16ykpy10), the Fundamental Research Funds for the
493 Central Universities, Sun Yat-sen University (19ykzd20), the General Funds of the National
494 Natural Science Foundation of China (32071451), the Guangdong Provincial Pearl River Talents
495 Program (2021QN02Y747), the Shenzhen Science and Technology Program
496 (RCYX20210706092100003), and by the Shenzhen Medical Research Funds grant (A2303005).

497 **Author contributions:** X.W., S.F., X.F., F.X., N.L., J.W. and E.D. designed the study and wrote
498 the manuscript, S.F., X.F., F.X. and X.W. supervised the study. Single-cell RNA and T/BCR
499 sequencing, RNA-Seq and ATAC-Seq involves library preparation and data analysis by N.L.,
500 J.W., E.D., T.C, Q.L. and J.Z., B.W., J.W., E.D., X.D., S.F., T.C and Y.Z. collected patient
501 samples and analyzed clinical data. S.F., N.L., J.W. and E.D. performed experiments and
502 interpreted the data. All authors critically revised the paper.

503 **Competing interests:** The authors declare that they have no competing interests.

504

505 **References**

- 506 1. Cramer, J. D., Burtness, B. & Ferris, R. L. Immunotherapy for head and neck cancer: Recent advances and
507 future directions. *Oral Oncology* **99**, 104460 (2019).
- 508 2. Bernier, J. *et al.* Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced
509 Head and Neck Cancer. *The New England Journal of Medicine* (2004).
- 510 3. Cooper, J. S. *et al.* Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell
511 Carcinoma of the Head and Neck. *N Engl J Med* **350**, 1937–1944 (2004).
- 512 4. Puram, S. V. *et al.* Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head
513 and Neck Cancer. *Cell* **171**, 1611-1624.e24 (2017).
- 514 5. Li, J. *et al.* Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-
515 deficient colorectal cancer. *Cancer Cell* **41**, 1152-1169.e7 (2023).
- 516 6. Oliveira, G. & Wu, C. J. Dynamics and specificities of T cells in cancer immunotherapy. *Nat Rev Cancer* **23**,
517 295–316 (2023).
- 518 7. Bhatia, A. & Kumar, Y. Cellular and molecular mechanisms in cancer immune escape: a comprehensive
519 review. *Expert Review of Clinical Immunology* **10**, 41–62 (2014).
- 520 8. Tumei, P. C. *et al.* PD-1 blockade induces responses by inhibiting adaptive immune resistance. *Nature* **515**,
521 568–571 (2014).
- 522 9. Galon, J. *et al.* Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. *The*
523 *Journal of Pathology* **232**, 199–209 (2014).
- 524 10. Fridman, W. H., Pagès, F., Sautès-Fridman, C. & Galon, J. The immune contexture in human tumours: impact
525 on clinical outcome. *Nat Rev Cancer* **12**, 298–306 (2012).
- 526 11. Yousefzadeh, M. J. *et al.* An aged immune system drives senescence and ageing of solid organs. *Nature* **594**,
527 100–105 (2021).
- 528 12. Goronzy, J. J. & Weyand, C. M. Understanding immunosenescence to improve responses to vaccines. *Nat*
529 *Immunol* **14**, 428–436 (2013).
- 530 13. Liu, Z. *et al.* Immunosenescence: molecular mechanisms and diseases. *Sig Transduct Target Ther* **8**, 200
531 (2023).
- 532 14. Zinatizadeh, M. R. *et al.* Immunosenescence and inflamm-ageing in COVID-19. *Ageing Research Reviews* **84**,
533 101818 (2023).

- 534 15. Ferrara, R. *et al.* Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer
535 Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. *Clinical Cancer Research*
536 **27**, 492–503 (2021).
- 537 16. Lian, J., Yue, Y., Yu, W. & Zhang, Y. Immunosenescence: a key player in cancer development. *J Hematol*
538 *Oncol* **13**, 151 (2020).
- 539 17. Liu, X. *et al.* Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor
540 immunity and immunotherapy. *J Immunother Cancer* **10**, e005020 (2022).
- 541 18. Park, M. D. *et al.* Hematopoietic aging promotes cancer by fueling IL-1 β -driven emergency myelopoiesis.
542 *Science* eadn0327 (2024) doi:10.1126/science.adn0327.
- 543 19. Vicente, R., Mausset-Bonnefont, A.-L., Jorgensen, C., Louis-Plence, P. & Brondello, J.-M. Cellular senescence
544 impact on immune cell fate and function. *Aging Cell* **15**, 400–406 (2016).
- 545 20. Pinti, M. *et al.* Aging of the immune system – focus on inflammation and vaccination. (2017).
- 546 21. Mittelbrunn, M. & Kroemer, G. Hallmarks of T cell aging. *Nat Immunol* **22**, 687–698 (2021).
- 547 22. López-Otín, C. Hallmarks of aging: An expanding universe.
- 548 23. Swanton, C. *et al.* Embracing cancer complexity: Hallmarks of systemic disease. *Cell* **187**, 1589–1616 (2024).
- 549 24. Luo, O. J. *et al.* Multidimensional single-cell analysis of human peripheral blood reveals characteristic features
550 of the immune system landscape in aging and frailty. *Nat Aging* **2**, 348–364 (2022).
- 551 25. Weivoda, M. M. *et al.* Identification of osteoclast-osteoblast coupling factors in humans reveals links between
552 bone and energy metabolism. *Nat Commun* **11**, 87 (2020).
- 553 26. Zhang, Y. *et al.* Single-cell analyses reveal key immune cell subsets associated with response to PD-L1
554 blockade in triple-negative breast cancer. *Cancer Cell* **39**, 1578-1593.e8 (2021).
- 555 27. Marta, G. N. *et al.* Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral
556 cavity cancer patients: Systematic review and meta-analysis. *Eur J Cancer* **51**, 2596–2603 (2015).
- 557 28. Liu, J. *et al.* Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic
558 Disease. *Cancer Discov* **6**, 1382–1399 (2016).
- 559 29. D, W. *et al.* Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in
560 resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial. *Nature*
561 *communications* **15**, (2024).

- 562 30. Sharma, P. & Allison, J. P. Dissecting the mechanisms of immune checkpoint therapy. *Nat Rev Immunol* **20**,
563 75–76 (2020).
- 564 31. Restifo, N. P., Dudley, M. E. & Rosenberg, S. A. Adoptive immunotherapy for cancer: harnessing the T cell
565 response. *Nat Rev Immunol* **12**, 269–281 (2012).
- 566 32. Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. *Science* **348**, 56–61 (2015).
- 567 33. Bagchi, S., Yuan, R. & Engleman, E. G. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical
568 Impact and Mechanisms of Response and Resistance. *Annu. Rev. Pathol. Mech. Dis.* **16**, 223–249 (2021).
- 569 34. Morad, G., Helmink, B. A., Sharma, P. & Wargo, J. A. Hallmarks of response, resistance, and toxicity to
570 immune checkpoint blockade. *Cell* **184**, 5309–5337 (2021).
- 571 35. De Miguel, M. & Calvo, E. Clinical Challenges of Immune Checkpoint Inhibitors. *Cancer Cell* **38**, 326–333
572 (2020).
- 573 36. Im, S. J. *et al.* Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. *Nature* **537**, 417–
574 421 (2016).
- 575 37. Siddiqui, I. *et al.* Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in
576 Response to Vaccination and Checkpoint Blockade Immunotherapy. *Immunity* **50**, 195–211.e10 (2019).
- 577 38. Utzschneider, D. T. *et al.* T Cell Factor 1-Expressing Memory-like CD8+ T Cells Sustain the Immune
578 Response to Chronic Viral Infections. *Immunity* **45**, 415–427 (2016).
- 579 39. Sade-Feldman, M. *et al.* Defining T Cell States Associated with Response to Checkpoint Immunotherapy in
580 Melanoma. *Cell* **175**, 998–1013.e20 (2018).
- 581 40. Li, H. *et al.* Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within
582 Human Melanoma. *Cell* **176**, 775–789.e18 (2019).
- 583 41. Van Der Leun, A. M., Thommen, D. S. & Schumacher, T. N. CD8+ T cell states in human cancer: insights
584 from single-cell analysis. *Nat Rev Cancer* **20**, 218–232 (2020).
- 585 42. Thommen, D. S. & Schumacher, T. N. T Cell Dysfunction in Cancer. *Cancer Cell* **33**, 547–562 (2018).
- 586 43. Philip, M. & Schietinger, A. CD8+ T cell differentiation and dysfunction in cancer. *Nat Rev Immunol* **22**, 209–
587 223 (2022).
- 588 44. Baker, D. J. *et al.* Naturally occurring p16Ink4a-positive cells shorten healthy lifespan. *Nature* **530**, 184–189
589 (2016).

- 590 45. Xu, M. *et al.* Senolytics improve physical function and increase lifespan in old age. *Nat Med* **24**, 1246–1256
591 (2018).
- 592 46. Saul, D. *et al.* A new gene set identifies senescent cells and predicts senescence-associated pathways across
593 tissues. *Nat Commun* **13**, 4827 (2022).
- 594 47. Huang, K. *et al.* AgeAnno: a knowledgebase of single-cell annotation of aging in human. *Nucleic Acids*
595 *Research* **51**, D805–D815 (2023).
- 596 48. Chang, J. *et al.* Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. *Nat*
597 *Med* **22**, 78–83 (2016).
- 598 49. Liu, H. *et al.* Rutin is a potent senomorphic agent to target senescent cells and can improve chemotherapeutic
599 efficacy. *Aging Cell* **23**, e13921 (2024).
- 600 50. Schafer, M. J. *et al.* Cellular senescence mediates fibrotic pulmonary disease. *Nat Commun* **8**, 14532 (2017).
- 601 51. Farr, J. N. *et al.* Targeting cellular senescence prevents age-related bone loss in mice. *Nat Med* **23**, 1072–1079
602 (2017).
- 603 52. Zhang, P. *et al.* Senolytic therapy alleviates A β -associated oligodendrocyte progenitor cell senescence and
604 cognitive deficits in an Alzheimer’s disease model. *Nat Neurosci* **22**, 719–728 (2019).
- 605 53. Novais, E. J. *et al.* Long-term treatment with senolytic drugs Dasatinib and Quercetin ameliorates age-
606 dependent intervertebral disc degeneration in mice. *Nat Commun* **12**, 5213 (2021).
- 607 54. Hickson, L. J. *et al.* Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of
608 Dasatinib plus Quercetin in individuals with diabetic kidney disease. *EBioMedicine* **47**, 446–456 (2019).
- 609 55. Justice, J. N. *et al.* Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot
610 study. *EBioMedicine* **40**, 554–563 (2019).
- 611 56. Jd, S. *et al.* Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell
612 Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. *JAMA oncology* **6**, (2020).
- 613 57. R, U. *et al.* Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human
614 Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. *Clinical cancer research* □: *an*
615 *official journal of the American Association for Cancer Research* **26**, (2020).
- 616 58. Wise-Draper, T. M. *et al.* Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable
617 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma. *Clin Cancer Res* **28**, 1345–1352
618 (2022).

- 619 59. Zinner, R. *et al.* 968P Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) outcomes in
620 HPV(-) resectable locally advanced head and neck cancer. *Annals of Oncology* **31**, S682 (2020).
- 621 60. Ce, H. *et al.* Adjuvant immunotherapy: the sting in the tail. *European journal of cancer (Oxford, England*
622 *1990)* **132**, (2020).
- 623 61. Soto-Herero, G., Gómez de Las Heras, M. M., Escrig-Larena, J. I. & Mittelbrunn, M. Extremely
624 Differentiated T Cell Subsets Contribute to Tissue Deterioration During Aging. *Annu Rev Immunol* **41**, 181–
625 205 (2023).
- 626 62. Cao, W. *et al.* TRIB2 safeguards naive T cell homeostasis during aging. *Cell Rep* **42**, 112195 (2023).
- 627 63. Sharma, S. *et al.* Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells:
628 implications for T-cell immunotherapy. *J Immunother Cancer* **11**, e006267 (2023).
- 629 64. Czystowska, M. *et al.* The immune signature of CD8(+)CCR7(+) T cells in the peripheral circulation associates
630 with disease recurrence in patients with HNSCC. *Clin Cancer Res* **19**, 889–899 (2013).

631

632

633 **Fig. 1 The results of the Phase II clinical trial (OOC-001) and scRNA-Seq data indicate that**
634 **MPR patients demonstrate increased diversity in immune response-related cell subtypes**
635 **and exhibit decreased expression of senescence markers.**

636 **a**, Waterfall plot depicting the treatment response of patients in the HNSCC neoadjuvant clinical
637 trial OOC-001 (NCT04718415, n=50). **b**, Pie charts depicting radiological and pathological
638 response rates in OOC-001. **c**, The changes and proportional statistics of TNM staging after
639 treatment for primary tumors in different patients. **d**, Schematic overview of the experimental
640 design and analytical workflow. **e**, UMAP plot of the immune cells that passed quality control.
641 Immune cell clusters are annotated and marked by color code. **f**, Prevalence of each single-cell
642 cluster (column) in all samples (n = 7) from different groupings of tissue (rows). Green dots
643 represent tumors samples, pink dots represent peripheral blood samples of pre-treatment (P0),
644 and red dots represent peripheral blood samples of post-treatment (P1). **g**, Estimation of size and
645 diversity of TCR repertoires for T cell clusters and BCR repertoires for B cell clusters between
646 MPR and noMPR groups in tumors. The number of TCR and BCR clonotypes estimated by
647 Chao1 (Materials and Methods) illustrates the predicted theoretical clonotype diversity. Data are
648 expressed as mean \pm s.e.m. **h**, Quantifications of immunofluorescent staining for senescent
649 markers P16 and P21 on paraffin sections from MPR and noMPR patients in two patient cohorts
650 (Cohort1 n=50, Cohort2 n=61). *P < 0.05, **P < 0.01, ***P < 0.001.

651

652 **Fig. 2 Patient responses to immunotherapy are associated with the expression of IAGs in**
653 **both T and B cell subsets, as well as the interaction of IGF1⁺ M ϕ with T and B cells.**

654 **a**, The IAGs significantly enriched in all immune cells in peripheral blood of frail elderly people
655 (GSE157007) and old people (PRJCA002856). **b**, The Ridge plot of IAGs score analysis for
656 major T cells clusters. **c**, Dot plot of intersection genes of HNSCC T cell DEGs and IAGs

657 between MPR and noMPR groups. **d**, UMAP of T cells from 4 paired tumor and blood samples
658 (12 samples total), highlighting shared clones between tumors (green) and P0 (pink, pre-
659 treatment blood) and P1 (red, post-treatment blood). **e**, Shared clonal cells ratio between tumor
660 (green) and P0 (pink, pre-treatment blood) and P1 (red, post-treatment blood) T cells from 4
661 paired tumor and blood samples. **f**, Paired TCR results Shows the overall number of TCR clones
662 (upper row), and the status of single clones after normalization (lower row). **g**,
663 Immunohistological staining quantifications of CD4 and S100A11 in HNSCC patients of two
664 cohorts (n=12 per group). **h**, Low expressions of S100A11 and high proportion of CD4 Naïve T
665 cells and memory B cells were significant associated with better OS. **i**, Hierarchical clustering
666 tree shows different models distinguish pathological responses of patients following the
667 combination therapy before surgery. T&B cells mean using the proportional distribution of T and
668 B cells and representative genes as a model to predict the patient's response. T cells alone or B
669 cells alone means using the proportional distribution of T cells or B cells and representative
670 genes as a model to predict patient response to treatment (the inner circle is the HNSCC patients'
671 number, and the outer circle is the cophenetic distance result to evaluate the effect). **j**, The
672 cellular compositions of myeloid cell clusters in P0 and P1 between MPR and noMPR groups in
673 HNSCC. **k**, Proportion of tumor-infiltrating IGF1⁺ Mφ was inversely correlated to the proportion
674 of tumor infiltrating CCR7⁺CD4 Naïve T and CD27⁻ Memory B in HNSCC. Pearson correlation
675 (two-sided).

676

677 **Fig. 3 The combination of dasatinib and quercetin with αPD-1 enhances therapeutic**
678 **efficacy in a chemically induced HNSCC mouse model by alleviating immunosenescence.**

679 **a**, Representative images of SA-β-gal and eosin staining for senescence markers in tumors and
680 adjacent normal tissues from HNSCC patients, along with paired quantitative analysis of SA-β-

681 gal positive areas. Scale bar, 50 μ m. **b**, Flowchart for Inducing HNSCC in C57 mice by adding
682 4NQO to drinking water (Top). Schematic representation of different groups in 4NQO-induced
683 mice, including Isotype intraperitoneal injection (Isotype), α PD-1 intraperitoneal injection (α PD-
684 1), α PD-1+Cisplatin intraperitoneal injection (α PD-1+CP), α PD-1 intraperitoneal injection plus
685 Dasatinib+Quercetin oral gavage (α PD-1+DQ). Isotype or α PD-1 was administered at 200 μ g per
686 mouse, cisplatin at 3 mg/kg, given on days 0, 7, and 14 of the experiment; Dasatinib (5 mg/kg)
687 and Quercetin (50 mg/kg) were administered on days 0, 3, 7, 10 and 14 (Bottom). **c**,
688 Immunohistological staining and staining area quantifications of SASP marker P16 and tumor
689 marker Pan-CK in the 4NQO induced HNSCC mice. Scale bar, 10 μ m. **d**, Representative images
690 of tongue of mice after receiving Isotype, α PD-1, α PD-1+CP or α PD-1+DQ treatment. White
691 arrows indicate tumor-like nodules (left); Dysplasia area quantifications of the mice treated with
692 Isotype, α PD-1, α PD-1+CP or α PD-1+DQ (n=6 per group) (right). **e**, Mouse over survival
693 (Surviving mice/Total number of mice x 100%) after receiving Isotype, α PD-1, α PD-1+CP or
694 α PD-1+DQ treatment (n=6 per group). **f**, Flow cytometry analysis of the expression of the
695 Senescence marker β -gal in immune cells within mouse tumors after receiving Isotype, α PD-1,
696 α PD-1+CP or α PD-1+DQ treatment (n=5 per group). **g**, Scatter plot showing the correlation
697 between the expression level of β -galactosidase in immune cells and the survival time of mice. **h**,
698 Flow cytometry analysis of CD4⁺, CD8⁺, and B cell proportions in 4-NQO mouse tumors after
699 receiving Isotype, α PD-1, α PD-1+CP or α PD-1+DQ treatment (n=6 per group). **i**, Expression
700 of senescence markers (*p16^{Ink4a}* and *p21^{Cip1}* mRNA) in CD4⁺ TILs in mouse tumors after
701 receiving Isotype, α PD-1, α PD-1+CP or α PD-1+DQ treatment (n=6 per group). **j**, Flow
702 cytometry analysis of CD4⁺ Naïve T cells proportions in mouse tumors after receiving Isotype,
703 α PD-1, α PD-1+CP or α PD-1+DQ treatment (n=6 per group). **k**, Representative images and
704 quantifications of immunofluorescent staining for CD4⁺CD62L⁺ T cells after receiving Isotype,

705 α PD-1, α PD-1+CP or α PD-1+DQ treatment (n=6 per group). The statistical analysis was
706 performed using t test (a), one-way ANOVA (c, d, f, h, i, j, k) and log-rank test (e). *P* values are
707 shown, and error bars indicate the mean \pm SEM.

708

709 **Fig. 4 Senolytics combined α PD-1 improve the efficacy of solid tumors in *Ercc1*^{+/-}**

710 **transgenic aging models by reducing SASP and increasing tumor-infiltrating CD4⁺ naïve T**

711 **cells. a**, Schematic diagram of orthotopic transplantation of tumor cells derived from the 4-NQO

712 model into the tongues of *Ercc1*^{+/-} transgenic mice. **b**, Representative photos of 3-month-old

713 *Ercc1*^{+/-} mice (*Ercc1*^{+/-} 3m), 9-month-old *Ercc1*^{+/-} mice (*Ercc1*^{+/-} 9m), and 20-month-old wild

714 type (WT 20m) C57 mice. **c**, Levels of 8-OHdG in spleens from *Ercc1*^{+/-} 3m, *Ercc1*^{+/-} 9m and

715 WT 20m mice (n=6 per group). **d**, Splenic weights normalized to body weight of *Ercc1*^{+/-} 3m,

716 *Ercc1*^{+/-} 9m and WT 20m mice (n=6 per group). **e**, Immunoblot detection of γ H2AX in spleen,

717 heart, liver and lung from 10-month-old WT or 10-month-old *Ercc1*^{+/-} (*Ercc1*^{+/-}) mice. **f**,

718 Representative images of H&E staining for 4N-MS1 tongue orthotopic transplant tumors. **g**, C57

719 mice were implanted with 5 \times 10⁵ 4N-MS1 cells into the tongue. Administration of different drug

720 treatments around the 7th day after 4N-MS1 implantation. Tumor growth curve showing the

721 tumor size after receiving Isotype, α PD-1, α PD-1+CP or α PD-1+DQ treatment (n=6 per group).

722 **h**, Multiplex bead-based protein analysis of lysate of mouse tongue tumor after receiving Isotype,

723 α PD-1, α PD-1+CP or α PD-1+DQ treatment (n=3 per group). **i**, Flow cytometry analysis of

724 CD4⁺ Naïve T cells proportions in mouse tumors after receiving Isotype, α PD-1, α PD-1+CP or

725 α PD-1+DQ treatment (n=6 per group). **j**, Representative images and quantitative analysis of

726 P21 and CD62L staining in 4N-MS1 tongue orthotopic transplant tumors. (n=6 per group). **k**,

727 Tumor growth curves for MB49 and E0771 transplant models after receiving Isotype, α PD-1,

728 α PD-1+CP or α PD-1+DQ treatment (n=6 per group). The statistical analysis was performed

729 using one-way ANOVA (c, d, h, j) and log-rank test (g, k). *P* values are shown, and error bars
730 indicate the mean \pm SEM.

731

732 **Fig. 5 ATAC-Seq and RNA-Seq analyses of CD4⁺ naïve T cells provide evidence for the**
733 **potential of α PD-1+DQ in the regulation of immunosenescence. a,** Pattern diagram of cell
734 sorting, as well as combined sequencing with ATAC-Seq and RNA-Seq. **b,** Heatmap illustrating
735 differences in the expression levels of T cell di-related genes among different groups. **c,** DEGs
736 ($\text{Log}_2\text{Foldchages} > 0.5$) of CD4 naïve T cells in tumors between α PD-1 and DQ and isotype
737 groups enriched GO terms. **d,** ATAC-seq tracks showing the representative genes chromatin
738 accessibility in the *Ccr7* and *S100a11* loci for CD4 naïve T cells in mouse tumors from isotype,
739 α PD-1 and DQ, and α PD-1 groups. **e,** RNA-seq and ATAC-seq detected GO terms that were
740 simultaneously enriched in the α PD-1 and DQ and isotype groups. **f,** Expression of *Ccr7*, *Lck*,
741 *Cfd*, *S100a11*, *p16^{Ink4a}*, *p21^{Cip1}* in CD4⁺ naïve T cells in mouse tumors after receiving Isotype,
742 α PD-1 or α PD-1+DQ treatment (n=□6 per group). **g,** Flow cytometry analysis of CCR7 and
743 LCK in CD4⁺ Naïve T cells proportions in mouse tumors after receiving Isotype, α PD-1 or α PD-
744 1+DQ treatment (n=□6 per group). **h,** Representative images of CCR7 and LCK staining in 4N-
745 MS1 tongue orthotopic transplant tumors. The statistical analysis was performed using one-way
746 ANOVA (f, g). *P* values are shown, and error bars indicate the mean \pm sem.

747

748 **Fig. 6 The Phase II clinical trial COIS-01 validated the safety and efficacy of combining**
749 **senolytic drugs with anti-PD-1 therapy. a,** Schematic representation of the clinical trial (COIS-
750 01) investigating the combination of ICIs with senolytics as neoadjuvant therapy for HNSCC. **b,**
751 The waterfall chart displays the clinical characteristics of 24 patients in the COIS-01 trial. **c,**
752 Representative imaging, HE pathology, and intraoral photographs of two pCR patients from
753 COIS-01. MM represents the masseter muscle, MB represents the mandible, and the tumor area

754 is indicated by the circled region. Scale bar, 50 μ m. **d**, The radar chart shows the proportions of
 755 various types of TRAEs in two clinical trials. **e**, Comparison of TRAEs between the COIS-01
 756 and OOC-001 clinical trials. **f**, Representative images and quantifications of immunofluorescent
 757 staining for CCR7⁺ Naïve T cells before and after treatment (n=□24 per group). The statistical
 758 analysis was performed using t test (**f**). *P* values are shown, and error bars indicate the mean \pm
 759 sem.

760

761 **Table 1 | Demographic and clinical characteristics of OOC-001**

Characteristics	Patients (n=50)
Age, median (range), years	56 (26, 80)
Sex, n (%)	
Male	38 (76.0)
Female	12 (24.0)
Smoking, n (%)	
Never	23 (46.0)
Former	9 (18.0)
Current	18 (36.0)
Primary tumor site, n (%)	
Oral tongue	23 (46.0)
Buccal mucosa	4 (8.0)
Gingiva	7 (14.0)
Floor of mouth	7 (14.0)
Oropharynx	7 (14.0)
Hard palate	2 (4.0)
ECOG scores, n (%)	
0	38 (76.0)
1	12 (24.0)
Pretreatment clinical T stage, n (%)	
T1	1 (2.0)
T2	22 (44.0)
T3	10 (20.0)
T4	1 (2.0)
T4a	16 (32.0)
Pretreatment clinical N stage, n (%)	
N0	29 (58.0)
N1	5 (10.0)
N2a	2 (4.0)

Characteristics	Patients (n=50)
N2b	5 (10.0)
N2c	9 (18.0)
AJCC overall clinical disease stage, n (%)	
II	20 (40.0)
III	8 (16.0)
IVA	22 (44.0)
Cycles of neoadjuvant therapy, n (%)	
2	24 (48.0)
3	22 (44.0)
4	4 (8.0)
HPV status, n (%)	
Positive	14 (28.0)
Negative	34 (68.0)
Not evaluable or missing	2 (4.0)
CPS, n (%)	
<10	15 (30.0)
≥10	33 (66.0)
Not evaluable or missing	2 (4.0)

762

763

764

Table 2 | Treatment-related adverse events of OOC-001 (n=51)

TRAEs, n (%)	Any grade	Grade 1-2	Grade 3-4
Any treatment-related adverse events	48 (94.1)	48 (94.1)	10 (19.6)
Alopecia	38 (74.5)	38 (74.5)	3 (5.9)
Asthenia or fatigue	27 (52.9)	27 (52.9)	0
Nausea	25 (49.0)	25 (49.0)	0
Arthralgia	13 (25.5)	13 (25.5)	0
Skin disorders	14 (27.5)	14 (27.5)	4 (7.8)
Diarrhoea	12 (23.5)	12 (23.5)	0
Gastroenteritis	10 (19.6)	9 (17.6)	1 (1.9)
Myalgia	8 (15.7)	8 (15.7)	0
Vomiting	8 (15.7)	8 (15.7)	0
Decreased appetite or anorexia	8 (15.7)	8 (15.7)	0
Paraesthesia	9 (17.6)	8 (15.7)	1 (1.9)
Pruritus	6 (11.8)	6 (11.8)	0
Anaemia	6 (11.8)	6 (11.8)	0
Hyperthyroidism	7 (13.7)	5 (9.8)	2 (3.9)
Increased aminotransferases	4 (7.8)	4 (7.8)	1 (1.9)
Leucopenia	2 (3.9)	1 (1.9)	2 (3.9)
Pyrexia	1 (1.9)	1 (1.9)	0

TRAEs, <i>n</i> (%)	Any grade	Grade 1-2	Grade 3-4
Thrombopenia	2 (3.9)	1 (1.9)	1 (1.9)
Hypothyroidism	1 (1.9)	1 (1.9)	0
Pulmonary infection	1 (1.9)	0	1 (1.9)

765

766

767

Table 3 | Demographic and clinical characteristics of COIS-01

Characteristics	Patients (<i>n</i>=24)
Age, median (range), years	55.5 (26, 73)
Sex, <i>n</i> (%)	
Male	13 (54.2)
Female	11 (45.8)
Smoking, <i>n</i> (%)	
No	19 (79.2)
Yes	5 (20.8)
Alcohol use, <i>n</i> (%)	
Never	22 (91.7)
Ever	2 (8.3)
Betel nut, <i>n</i> (%)	
Never	22 (91.7)
Ever	2 (8.3)
Primary tumor site, <i>n</i> (%)	
Buccal mucosa	3 (12.5)
Gingiva	4 (16.7)
Oropharynx	1 (4.2)
Tongue	16 (66.7)
HPV status, <i>n</i> (%)	
Positive	4 (16.7)
Negative	14 (58.3)
Not evaluable or missing	6 (25)
Pretreatment clinical T stage, <i>n</i> (%)	
T2	22 (91.7)
T4a	2 (8.3)
Pretreatment clinical N stage, <i>n</i> (%)	
N0	22 (91.7)
N1	1 (4.2)
N2a	1 (4.2)
AJCC overall clinical disease stage, <i>n</i> (%)	
II	21 (87.5)
III	1 (4.2)

Characteristics	Patients (n=24)
IVA	2 (8.3)
CPS, n (%)	
<1	1 (4.2)
1-19	15 (62.5)
≥20	8 (33.3)

768

769

Table 4 | Treatment-related adverse events of COIS-01 (n=24)

TRAEs, n (%)	Any grade	Grade 1-2	Grade 3-4
Any treatment-related adverse events	18 (75.0)	18 (75.0)	1 (4.2)
Alopecia	0	0	0
Asthenia or fatigue	6 (25.0)	6 (25.0)	0
Nausea	4 (16.7)	4 (16.7)	0
Arthralgia	3 (12.5)	3 (12.5)	0
Skin disorders	0	0	0
Diarrhoea	7 (29.2)	7 (29.2)	0
Gastroenteritis	1 (4.2)	0	1 (4.2)
Myalgia	3 (12.5)	3 (12.5)	0
Vomiting	2 (8.3)	2 (8.3)	0
Decreased appetite or anorexia	2 (8.3)	2 (8.3)	0
Paraesthesia	1 (4.2)	1 (4.2)	0
Pruritus	6 (25.0)	6 (25.0)	0
Anaemia	1 (4.2)	1 (4.2)	0
Hyperthyroidism	1 (4.2)	1 (4.2)	0
Increased aminotransferases	2 (8.3)	2 (8.3)	0
Leucopenia	0	0	0
Pyrexia	0	0	0
Thrombopenia	0	0	0
Hypothyroidism	1 (4.2)	1 (4.2)	0
Pulmonary infection	0	0	0

770

771

772

Methods:

773

Patients

774

The inclusion criteria and exclusion criteria for OOC-001 and COIS-01 are the same.

775 Eligibility criteria included: age 18-80 years; newly diagnosed histologically or cytologically
776 confirmed HNSCC; stage II-IVA AJCC 8th edition; disease was determined resectable by the
777 treating head and neck surgeon; Eastern Cooperative Oncology Group (ECOG) performance
778 status ≤ 1 ; and adequate organ function.

779 Key exclusion criteria included: prior therapy with immunotherapy or or have had invasive
780 malignancies and related treatments in the past 5 years; autoimmune diseases requiring recent
781 systemic steroid use, active infections, or a history of allergic reactions to similar compounds;
782 pregnancy, psychiatric disorders, HIV, active Hepatitis B or C.

783 **Trial design and treatments**

784 **OOC-001 (NCT04718415)** This study is a prospective, single-arm, phase II clinical study. This
785 study plans to enroll 51 patients with resectable oral or oropharyngeal squamous cell carcinoma,
786 and preoperatively use sintilimab, carboplatin, and albumin-bound paclitaxel. Tumor tissue and
787 paracancerous tissue of patients will be collected to observe the changes of imaging and
788 pathology before and after treatment. At the same time, clinical information of patients, such as
789 pathological grade, stage, treatment, prognosis, serology, imaging, etc., will be collected to
790 evaluate the safety and feasibility of sintilimab combined with carboplatin and albumin-bound
791 paclitaxel for neoadjuvant treatment of resectable oral and oropharyngeal squamous cell
792 carcinoma.

793 Patients received treatment with sintilimab, nab-paclitaxel, and carboplatin for up to 2 to 4 cycles:
794 Sintilimab (IV), dose: 200 mg, day: 1, cycle length: 21 days; Carboplatin (IV), dose: 300 mg/m²,
795 day: 1, cycle length: 21 days; Nab-paclitaxel (IV), dose: 260 mg/m², day: 1, cycle length: 21
796 days. Surgical therapy will be performed at the discretion of the treating surgeon according to
797 standard of care.

798 **COIS-01 (NCT05724329)** This study is a prospective, open-label, single-center, phase II clinical
799 study evaluating the safety and efficacy of the combination of tislelizumab with dasatinib and
800 quercetin in the new adjuvant treatment of resectable head and neck squamous cell carcinoma.
801 This research aims to expand the indications for new adjuvant immunotherapy in solid tumors
802 and provide a new strategy for significantly improving the prognosis of head and neck squamous
803 cell carcinoma patients. This study plans to enroll 24 participants with resectable head and neck
804 squamous cell carcinoma. We will collect tumor tissues, adjacent tissues, fat, epidermis, whole
805 blood samples, saliva, feces, and urine from the patients. The study aims to observe imaging and
806 pathological changes before and after treatment while also collecting clinical information, such
807 as pathological grading, staging, treatment details, prognosis, and serological and imaging data.
808 Patients will receive neoadjuvant treatment with tislelizumab, dasatinib, and quercetin for up to 3
809 cycles (cycle length: 21 days): Tislelizumab (IV), dose: 200 mg, day: 1; Dasatinib (PO), dose:
810 100 mg/day, days: 1, 2, 3; Quercetin (PO), dose: 1250 mg/day, days: 1, 2, 3. Surgical therapy
811 will be performed at the discretion of the treating surgeon according to standard of care.
812 Following surgical resection, participants will receive adjuvant therapy: Tislelizumab (200 mg,
813 day: 1) for cycles 1 to 15; Dasatinib (100 mg/day, days: 1, 2, 3) for cycles 1, 2, 3, 8, 9, and 10;
814 Quercetin (1250 mg/day, days: 1, 2, 3) for cycles 1, 2, 3, 8, 9, and 10.

815 **Ethics statement**

816 This study includes two independent clinical trials for HNSCC: OOC-001 (NCT04718415) and
817 COIS-01 (NCT05724329). Eligible HNSCC patients received prior approval from the
818 Institutional Review Board (IRB) at Sun Yat-sen Memorial Hospital, Sun Yat-sen University,
819 and were required to provide written informed consent to participate in the study. All patients
820 were diagnosed with HNSCC by expert histopathologists, and all invasive procedures and
821 systemic treatments were ordered by the patients' attending physicians, individually determined

822 based on the response after the administration of pharmacological drugs. All images of research
823 participants in this article have obtained consent for publication.

824 **End points**

825 **OOC-001** The primary endpoint were Safety, defined as the severity of treatment-related
826 adverse events will be graded according to NCI CTCAE (version 5.0) during the study and
827 follow-up; the major pathological response rate, defined as the proportion of participants with
828 viable tumor cells $\leq 10\%$ in the resected specimens. Secondary endpoints were Disease-Free
829 Survival, defined as the time from treatment until the date of the first relapse (local/regional
830 recurrence or distant metastasis) or death (from any cause) whichever comes firsts; Overall
831 Survival, defined as the time from day 1 of study treatment until death from any cause; Objective
832 Response Rate (ORR), defined as assessed through imaging according to the Response
833 Evaluation Criteria in Solid Tumors (RECIST 1.1); Surgery Delay Rate, defined as participants
834 who cannot undergo surgery within 8 weeks after the last dose will be classified as having
835 surgery delay.

836 **COIS-01** The primary endpoint was the major pathological response rate, defined as the
837 proportion of participants with viable tumor cells $\leq 10\%$ in the resected specimens. Secondary
838 endpoints were Safety, defined as the severity of treatment-related adverse events will be graded
839 according to NCI CTCAE (version 5.0) during the study and follow-up; Overall Survival,
840 defined as time from enrollment to the date of death from any cause; Disease-Free Survival,
841 defined as the time from treatment until the date of the first relapse (local/regional recurrence or
842 distant metastasis) or death (from any cause) whichever comes firsts; Objective Response Rate
843 (ORR), defined as assessed through imaging according to the Response Evaluation Criteria in
844 Solid Tumors (RECIST 1.1); Surgery Delay Rate, defined as participants who cannot undergo
845 surgery within 8 weeks after the last dose will be classified as having surgery delay.

846 **Statistical analysis of clinical trials**

847 **OOC-001** All enrolled cases that have received at least one dose of the investigational drug and
848 have safety records post-treatment will be included in the Safety Analysis Set. Effectiveness
849 analysis will be conducted for all enrolled cases that received neoadjuvant therapy in conjunction
850 with surgery, biopsy, or chemoradiotherapy.

851 This is a single-arm, pilot study with a fixed sample size. No strict hypothesis testing will be
852 conducted, and the study plans to enroll 51 participants. The MPR rate and 95% CI were
853 calculated using the Clopper-Pearson method. The OS, and DFS were plotted using the Kaplan-
854 Meier method. Other clinical outcomes, demographic characteristics, and safety were
855 summarized descriptively. We performed all statistical tests using GraphPad Prism 9.0.0.

856 **COIS-01** Effectiveness analysis will be conducted for all enrolled cases that received at least one
857 dose of the drug according to the Intent-to-Treat (ITT) principle. All enrolled cases that have
858 received at least one dose of the investigational drug and have safety records post-treatment will
859 be included in the Safety Analysis Set.

860 Based on a two-sided type 1 error of 0.05 and a power of 90%, we estimated that a total sample
861 size of 24 patients would be required to show an improvement of 23% in the major pathological
862 response rate after DQ (ie, from 7% in the previous study⁵⁸ to 30% in the current study).

863 Assuming a 5% dropout rate, the final sample size was estimated to comprise 24 patients.

864 The MPR rate and 95% CI were calculated using the Clopper-Pearson method. The OS, and DFS
865 were plotted using the Kaplan-Meier method. Other clinical outcomes, demographic
866 characteristics, and safety were summarized descriptively. We performed all statistical tests
867 using GraphPad Prism 9.0.0.

868 **Human specimens**

869 The eight patients used for the scRNA-Seq study were part of the OOC-001 clinical trial and
870 received the described treatment regimen. Specifically, all patients had their primary tumor tissue
871 and peripheral blood collected through biopsy at the time of enrollment, and the peripheral blood
872 was collected after sintilimab in combination with carboplatin and nab-paclitaxel treatment
873 before surgery. Among the 7 patients (SH1-SH7) who underwent surgery, 3 patients are MPR,
874 and 4 patients are noMPR. Paired biopsy samples of primary tumor tissue and peripheral blood
875 were collected at baseline before treatment, and peripheral blood samples were collected 3 weeks
876 after the first dosing cycle. Except for SH1, peripheral blood samples were collected from the
877 other patients before and after the first medication cycle for matching. For patient SH1, blood
878 samples were collected only before the first medication cycle. Peripheral blood samples were
879 collected after the second medication cycle for SH1, SH2, SH3, and SH4, and peripheral blood
880 samples were collected for SH3, SH4, and SH7 after the third medication cycle. Paraffin sections
881 from two ongoing clinical study patient cohorts were used for immunofluorescence staining of
882 senescent markers P16 and P21. This included 33 MPR patients and 17 noMPR patients from
883 OOC-001, as well as 37 MPR patients and 24 noMPR patients from REDUCTION-I. Another set
884 from COIS-01 collected paraffin sections from 7 patients for immunofluorescence staining
885 before and after treatment.

886 **Sample collection and processing**

887 Peripheral blood mononuclear cells (PBMCs) were isolated according to the manufacturer's
888 protocol. Briefly, before the start of treatment, 5 mL of fresh peripheral blood was collected in
889 EDTA anticoagulated tubes and subsequently extracted with Lymphoprep™ (Stem Cells)
890 solution. After centrifugation, carefully transfer lymphocytes to a new 50 mL tube and wash with
891 PBS. Next, incubate the lymphocytes for 10 minutes to lyse the blood cells. Finally, cells were
892 resuspended in sorting buffer containing PBS plus 2% FBS.

893 For tumor biopsy samples, cut tissue with a diameter of about 5 mm at the junction of the tumor
894 and normal tissue as a representative sample. All 7 tumor biopsy samples were collected as a
895 discovery cohort through routine clinical practice and then stored in MACS Tissue Storage
896 Solution (Miltenyi). Fresh biopsy samples of oral HNSCC were minced and isolated using a
897 human tumor isolation kit (Miltenyi), followed by enzymatic digestion on a rotor at 37°C for 45–
898 60 min. The detached cells were then passed through 70 µm and 40 µm cell filters (Biosharp)
899 and centrifuged at 300 × g for 10 min. Pelleted cells were suspended in red blood cell lysis buffer
900 (Thermo-Fisher) and incubated on ice for 2 min, then washed and resuspended in phosphate
901 buffer supplemented with 2% fetal bovine serum (FBS, ExCell) PBS twice in saline (PBS,
902 Gibco). The viability of all samples was confirmed to be >90% using the trypan blue (Thermo-
903 Fisher) exclusion method.

904 **Single-cell RNA-seq library and TCR-seq library preparation and sequencing**

905 According to the manufacturer's protocol, scRNA-seq libraries were constructed. In summary,
906 the density of cells was determined after washing once with PBS containing 0.04% bovine serum
907 albumin (BSA, Invitrogen). Next, 2×10^5 cells were loaded on a 10x Genomics GemCode Single
908 cell instrument (10x Genomics) that generates single-cell Gel Bead-In-EMulsion (GEMs).
909 Libraries were generated and sequenced from the cDNAs with the Chromium Next GEM
910 Automated Single Cell 3' cDNA Kitv3.1 (10x Genomics). Upon dissolution of the Gel Bead in a
911 GEM, primers were released and mixed with cell lysate and Master Mix. Barcoded, full length
912 cDNAs were then reverse-transcribed from polyadenylated mRNA. Full-length, barcoded
913 cDNAs were then amplified by quantitative real-time PCR (qRT-PCR) for library construction.
914 Finally, single-cell RNA libraries were sequenced by an Illumina HiSeq X Ten sequencer with
915 150 bp paired-end reads.

916 After reverse transcription and cell barcoding, the cDNA was de-emulsified and purified using
917 silane magnetic beads, followed by PCR amplification. The amplified cDNA was then used for
918 5' gene expression library construction and TCR V(D)J targeted enrichment amplification using
919 the Illumina® bridge. Libraries prepared according to the manufacturer's user guide were then
920 purified and analyzed for quality assessment. Single-cell RNA and TCR V(D)J libraries were
921 sequenced by an Illumina HiSeq X Ten sequencer using 150 bp paired-end reads.

922 **Bulk TCR-seq library preparation and sequencing**

923 Whole Blood Samples Blood was collected in EDTA tubes and sent to isolated PBMCs, and
924 DNA was extracted for TCR β analysis by immunoSEQ⁶⁵. Briefly, extracted genomic DNA was
925 amplified using a bias-controlled multiplex PCR system, followed by high-throughput
926 sequencing. Raw data processing and analysis were performed by immunoSEQ. Subsequently,
927 we used the International ImMunoGeneTics Information System (IMGT; <http://imgt.cines.fr>)
928 database for comparison. After the alignment, the relative abundance of each TCR β CDR3
929 sequence was clarified and calculated. Furthermore, we use batch correction to eliminate batch
930 effects across different datasets. Subsequently, multiple TCR data statistics were performed.

931 **Bulk ATAC and RNA isolation and sequencing**

932 Isolation, library construction and sequencing of bulk ATAC and RNA were performed at Gene
933 Denovo Biotechnology Co. (Guangzhou, China). For ATAC sequencing, CD4 naïve cells from
934 C57 mouse tongue tumors were extracted. Tn5 transposase was added to the nuclear suspension.
935 After the reaction was completed, the DNA fragment was purified; the amplified product was
936 then used for PCR amplification. The fragments were purified using AMPure XP magnetic beads
937 (Beckman Coulter, Brea, CA, USA) to construct a sequencing library. After the library
938 construction was completed, Agilent 2100 (Agilent, Santa Clara, CA) was used to detect the
939 quality of the library. Libraries that pass the quality inspection will be used for on-machine

940 sequencing (Novaseq 6000) to obtain sequence information of the open chromatin region
941 fragments to be tested.

942 Extraction of CD4 naïve cells from C57 mouse tongue tumors. Total RNA was extracted using
943 Trizol reagent kit (Invitrogen) according to the manufacturer's protocol. RNA quality was
944 assessed on an Agilent 2100 Bioanalyzer (Agilent Technologies). After total RNA was extracted,
945 eukaryotic mRNA was enriched by Oligo(dT) beads. Then the enriched mRNA was reversely
946 transcribed into cDNA by using NEBNext Ultra RNA Library Prep Kit for Illumina (NEB #7530,
947 New England Biolabs). The resulting cDNA library was sequenced using Illumina Novaseq6000
948 by Gene Denovo Biotechnology Co. (Guangzhou, China).

949 **scRNA-Seq data processing**

950 The Cell Ranger toolkit (version 3.1.0) provided by 10x Genomics was applied to aggregate raw
951 data, filter low-quality reads, align reads to the human reference genome (GRCh38), assign cell
952 barcodes and generate a UMI matrix. The toolkit Scanpy (version 1.9.3)⁶⁶ was used to analyze
953 single-cell RNA sequencing (scRNA-Seq) data. Specifically, the original UMI matrix was
954 processed to filter out genes expressed in less than 10 cells and cells with less than 200 genes.
955 We further quantified the number of genes and UMI counts per cell and maintained thresholds
956 for high-quality cells of 1000-50,000 UMIs, 400-6,000 genes and less than 10% mitochondrial
957 gene counts, ensuring that most heterogeneous cell types were incorporated into downstream
958 analyses. Scrublet (version 0.2.3)⁶⁷ was then applied to each sequencing library to remove
959 potential doublets, using default parameters. The normalized expression matrix was calculated
960 from raw UMI counts normalized to total counts per cell (library size) and then scaled by 1e4
961 and log-transformed.

962 **Dimensionality reduction and unsupervised clustering of scRNA-seq data**

963 Dimensionality reduction and unsupervised clustering were performed according to standard
964 workflows in Scanpy ⁶⁶. Briefly, use highly variable genes (HVG) based on the
965 `highly_variable_genes` default parameters. Unwanted sources of variation, including total counts,
966 and mitochondrial gene counts were further regressed from the normalized expression matrix.
967 Primary component analysis (PCA) was performed on the variable gene matrix to reduce noise
968 and the top 50 components were used for downstream analysis. To correct for batch effects
969 across different patients, we applied BBKNN to generate a batch-balanced k-nearest neighbor
970 (KNN) map, which identifies the top neighbors of each cell in each batch individually, rather
971 than the entire pool of cells ⁶⁷. The Leiden algorithm is then applied to such nearest neighbor
972 graphs to detect communities and find cell clusters ⁶⁸. It is worth noting that the same principal
973 components are also used for nonlinear dimensionality reduction to generate uniform
974 distributions for visualization in Uniform Manifold Approximation and Projection (UMAP).
975 After the first round of unsupervised clustering, we annotated each cell cluster according to
976 canonical immune cell markers and identified the main immune cell types, including T cells, NK
977 cells, B cells, myeloid cells, fibroblasts, endothelial cells and tumor cells. Use the
978 `rank_genes_groups` function with parameter `method Wilcoxon` to detect marker gene.

979 **TCR sequences assembly**

980 Applying the TCR sequence assembly Cell Ranger toolkit (version 3.1.0) provided by 10x
981 Genomics will perform FASTQ sequence quality filtering, sequence alignment, V(D)J assembly
982 and TCR $\alpha\beta$ pairing. Only TCRs containing paired TRAV-CDR3-TRAJ and TRBV-CDR3-
983 TRBJ-TRBC chains were considered valid and retained for downstream analysis. Each cell is
984 assigned a pair of α and β chains with the highest UMI count. Cells with identical TCR pairs are
985 defined as clonal and are thought to originate from a common ancestor.

986 **Calculation of Diversity Index**

987 Characterize the immune repertoire by examining diversity and clonality. Immune repertoire
988 analysis involves a variety of diversity indices, such as Chao1 index, Clone Diversity Index,
989 Richness index and Shannon index²⁴.

990 **Bulk RNA-sequencing and ATAC-sequencing data processing**

991 For bulk RNA-Seq data, reads were filtered using FASTQ (0.23.3) default parameters, and then
992 clean reads were aligned to the mouse genome GRCm39 and gencode. vM30 annotations were
993 using STAR (2.7.10b) and using RSEM (1.3.1) rsem-calculate-expression is in quantitative
994 analysis of gene expression. Difference analysis was done using DESeq2 (1.42.0).

995 For bulk ATAC data, use FASTQ (0.23.3) for quality control, then use bwa (0.7.17) to align the
996 reads to the reference genome (GRCm39), and peak using Genrich (0.6.1, [https://github.com](https://github.com/jsh58/Genrich)
997 [/jsh58/Genrich](https://github.com/jsh58/Genrich)). Peak is annotated to gencode. vM30 through annotatePeaks.pl of HOMER
998 (4.11). The difference peak is obtained by BEDTools (v2.31.1) subtract.
999 (<https://github.com/jsh58/ATAC-seq2>)

1000 **Generation of Immunosenescence gene set**

1001 Our own senescence-related gene set was generated by combining genes reported to be enriched
1002 in senescent immune cells in previous studies and experimentally validated in at least human or
1003 mouse cells. We screened 1745 studies, but after removing studies reporting duplicates, case
1004 reports, non-human genes, and non-high-throughput sequencing, a list of 6 studies was
1005 developed (Senmayo⁴⁶, GSE157007²⁴, HRA000624⁶⁹, HRA000395⁷⁰, HRA000615⁷¹ and
1006 HSA000203⁷² and 1 database (<https://genomics.senescence.info/cells/>)). We screen immune
1007 cells and compare samples from young and old people to obtain differential genes that are highly
1008 expressed in the elderly, remove duplicate genes, and screen genes that appear in at least two
1009 data sets. Based on the enrichment of relevant gene pathways and machines Learning method,
1010 154 genes constituting the immunosenescence gene set were identified (Supplementary Table 4).

1011 **GO enrichment analysis and Gene set enrichment analysis (GSEA)**

1012 Using the R package ClusterProfiler (version 4.8.3), gene function annotation and GO were
1013 performed on genes that were down-regulated and up-regulated in T cells and B cells in the MPR
1014 and noMPR groups, as well as differential genes between macrophages and monocytes and other
1015 cells. Analysis, a program that supports statistical analysis and visualization of functional
1016 profiles of genes and gene clusters.

1017 GSEA was performed by the GSEA software (<http://software.broadinstitute.org/gsea/index.jsp>)

1018 ⁷³. Gene sets used in this article were c2.cp.kegg.v6.2.symbols.gmt downloaded from the
1019 Molecular Signatures Database (MSigDB, [http://](http://software.broadinstitute.org/gsea/msigdb/index.jsp)
1020 software.broadinstitute.org/gsea/msigdb/index.jsp).

1021 **Gene Set Score Analysis**

1022 The scoregenes function in Scanpy is used to calculate the module score of a gene expression
1023 program in a single cell. First, all analyzed genes were binned according to their average
1024 expression, and control genes were randomly selected from each bin. Then, the average
1025 expression value of the gene set at the single-cell level minus the aggregate expression of the
1026 control gene set was calculated. The gene set was obtained from the immunosenescence gene set
1027 constructed by ourselves. The genes in each gene set are listed in Supplementary Table 4.

1028 **Cell-cell interaction**

1029 We used the CellChat package (1.6.1), which allows analysis of scRNA-Seq data. We studied the
1030 interaction between immune cells (i.e. T cells and B cells) and myeloid cells (i.e. macrophages
1031 and monocytes), one of which contributes ligands or receptors during the interaction, using
1032 CellChat Signaling pathway networks are analyzed and visualized.

1033 **Trajectory inference of immune cell subsets across tissues**

1034 The status of immune cell subpopulations in the periphery and in tumors is dynamic, and they
1035 may differentiate into different cell states and exert different biological functions in different
1036 patients. We use the pseudo-temporal inference algorithm Monocle 2 for trajectory analysis to
1037 reconstruct the cell differentiation trajectory of immune cells across tissues, reveal the
1038 progression of cells and reconstruct the trajectory of cells progressing through biological
1039 processes under study.

1040 **Survival analysis**

1041 Survival analysis uses TCGA and HNSCC data to evaluate the prognostic performance of
1042 different immune cell populations. Gene expression data and clinical information of HNSCC
1043 patients were downloaded from cBioPortal (<https://www.cbioportal.org/study/clinicalData>). Use
1044 Cibersort and Xcell to extract T cells and B cells subtypes and group them based on the
1045 expression levels of characteristic genes. Specifically, HNSCC patients were divided into four
1046 groups based on the median proportion of immune cell subsets and the median mean expression
1047 of a given signature gene. In the analysis of myeloid cells, a subset of cells within a single cell is
1048 characterized using a set of signature genes, defined based on a combination of typical marker
1049 genes for major immune cell types and cluster-specific marker genes. Specifically, for different
1050 macrophage clusters, we used the typical IGF1⁺ Mφ marker genes "*CD276*", "*APOE*", "*TREM2*",
1051 "*HTRA1*", "*PTGRI*", "*RBPI*", "*IGF1*", "*CDKN1A*", "*CD81*" define its signature. HNSCC
1052 patients were divided into two groups based on the median of the mean expression of the given
1053 signature. Survival analysis was performed using the COX proportional hazards model
1054 implemented in the R package "survival".

1055 **Hierarchical Clustering**

1056 In the end, cell subpopulations and characteristic genes were used to construct a neoadjuvant
1057 treatment model for patients before surgery, and a hierarchical clustering method was used to

1058 create groups. Cophenetic distance was used to evaluate the objects in the group so that they
1059 were like each other and different from objects in other groups. Verify different cell
1060 subpopulations and gene signatures to evaluate the efficacy of neoadjuvant therapy in patients
1061 before surgery.

1062 **TNBC single cell RNA sequencing data processing**

1063 TNBC single-cell RNA sequencing data comes from GSE169246. Patients who received
1064 combined neoadjuvant chemotherapy and immune therapy before surgery were screened, and the
1065 patients were divided into PR (response) and SD (non-response) groups based on the
1066 corresponding imaging conditions. The rest of the analysis process as before, similar cell
1067 subpopulations were evaluated after dimensionality reduction clustering, and senescent immune
1068 cells were evaluated on the cell subpopulations. Hierarchical clustering was used to verify the
1069 effect of different cell subpopulations and gene characteristics on patients receiving neoadjuvant
1070 therapy before surgery to evaluate.

1071 **Animal experiments.**

1072 Twelve-month-old female C57BL/6J mice (SPF grade), weighing 18-20 g, along with *Ercc1*
1073 knockout mice, were purchased from GemPharmatech Co., Ltd. The housing conditions were
1074 maintained at a temperature of 18-22°C and a humidity of 50-60%. Water was changed 2-3 times
1075 per week, and the mice were kept under a 12-hour light/dark cycle. The animal experiments in
1076 this study were conducted with the approval of the Animal Ethics Committee of Sun Yat-sen
1077 University and the Institutional Animal Care and Use Committee at the Shenzhen Institutes of
1078 Advanced Technology, Chinese Academy of Sciences (CAS). All experimental procedures
1079 adhered to the Regulations for the Administration of Affairs Concerning Experimental Animals
1080 issued by the People's Republic of China. The animal experiments also complied with laboratory
1081 practice guidelines and standard operating procedures.

1082 **4-NQO-induced mouse HNSCC model.**

1083 4NQO (Sigma, USA) was prepared at a concentration of 500 mg·L⁻¹ in 1,2-propanediol and
1084 stored in a light-protected container at 4 °C. For administration, the 4NQO solution was diluted
1085 with distilled water to a final concentration of 50 mg·L⁻¹ and provided in light-protected bottles
1086 as drinking water for female C57 mice (12 months old) for 16 weeks. After 16 weeks, the mice
1087 were switched to distilled water until the end of the experiment. Starting from the initiation of
1088 4NQO administration, one mouse was randomly sacrificed each week to collect tongue tissue for
1089 paraffin embedding. The tissues were routinely embedded, and serial sections were made until
1090 no tissue remained. Sections with intact tissue samples were selected for further analysis.
1091 Hematoxylin-eosin (HE) staining was performed according to standard protocols. Pathological
1092 diagnosis was conducted following the WHO 2005 diagnostic criteria.

1093 **Establishment of cell lines and tissue culture.**

1094 Mice fed with 4NQO for 28-32 weeks (all exhibiting visible tumors) were euthanized by cervical
1095 dislocation under anesthesia. The mice were disinfected by soaking in 75% ethanol for 1 minute,
1096 followed by two rounds of povidone-iodine disinfection of the oral cavity. Tumor tissues were
1097 excised from the oral cavity using micro scissors and a scalpel. The tissues were then minced
1098 with ophthalmic scissors in a small volume of PBS and digested with enzymes (in 2.5% trypsin-
1099 DMEM) for 30 minutes in a shaking water bath at 37°C. After digestion, the cell suspension was
1100 filtered through a 70 µm strainer. The isolated tumor cells were plated at a density of 2 million
1101 cells per well in 6-well tissue culture plates and continuously cultured to select for cancer cells.

1102 **SA-β-gal staining**

1103 Tumor tissues excised during surgery were washed three times with saline and then fixed in 4%
1104 PFA for 12 hours. The tissues were embedded in cryo-embedding medium (OCT) and rapidly
1105 frozen in liquid nitrogen. Serial sections of 5 µm thickness were cut using a cryostat. β-

1106 Galactosidase staining was performed according to the manufacturer's protocol (C0602,
1107 Beyotime), followed by nuclear staining with eosin. After staining, images were captured under a
1108 20x optical microscope.

1109 **RNA isolation and qRT-PCR**

1110 Add 1 mL of TRIzol to a sterile culture tube. Place the frozen tissue into the tube and
1111 homogenize on ice using a homogenizer set to 25/30, grinding the tissue twice for 10 seconds
1112 each time. Total RNA was isolated using the TRIzol method according to the manufacturer's
1113 instructions (Thermo Fisher). Subsequently, cDNA synthesis was performed using the
1114 SuperScript IV VILO Master Mix (Thermo Fisher) following the manufacturer's protocol, with
1115 reactions done in duplicate for each sample. Data were analyzed using the $\Delta\Delta\text{Ct}$ method, and
1116 expression levels were normalized to *Gapdh*.

1117 **Quantitation of 8-OHdG DNA lesions**

1118 Tissues from mice were analysed for 8-OHdG levels using the ELISA kit (Abcam) according to
1119 manufacturer's specifications.

1120 **Immunoblotting**

1121 After rapidly freezing the spleen, liver, heart, and lung tissues from mice, homogenize the tissues
1122 using a tissue homogenizer. Lyse the cells with RIPA buffer (Thermo-Fisher) and collect the
1123 lysate into centrifuge tubes. Mix the lysate on a shaker for 4-15 minutes, then centrifuge at
1124 14,000g for 15 minutes at 4°C. Discard the pellet and measure the protein concentration in the
1125 supernatant using the Bradford method. Load equal amounts of protein and molecular weight
1126 markers into the wells of an SDS-PAGE gel. Load 20-30 μg of total protein from the cell lysate
1127 or tissue homogenate per well. Transfer the proteins from the gel to a membrane and block the
1128 membrane with blocking buffer at room temperature for 1 hour. Incubate the membrane
1129 overnight at 4°C with anti- γH2AX (1:2000) and anti-GAPDH (1:5000) antibodies in blocking

1130 buffer. Wash the membrane three times with TBST, each wash lasting 5 minutes. Incubate the
1131 membrane with a secondary antibody conjugate in blocking buffer at room temperature for 1
1132 hour, then wash and develop using ECL (Thermo-Fisher).

1133 **TIL isolation and flow cytometry**

1134 After euthanizing the mice by cervical dislocation, tumor tissues were excised and placed on ice
1135 for 10 minutes. The tissues were washed twice with 1× PBS, minced, and digested with a
1136 solution containing collagenase II (1 mg/mL), collagenase IV (1 mg/mL), and DNase I (100
1137 U/mL) for 30 minutes. The digested tumor tissues were filtered through a 70 μm strainer and
1138 washed once with 1× PBS to stop the digestion. The cell suspension was washed again with 1×
1139 PBS. A 10 μL aliquot of the cell suspension was diluted 10-fold with 1× PBS for cell counting.
1140 The single-cell suspension was adjusted to a cell density of 1×10^7 cells/mL, and 100 μL of the
1141 cell suspension was taken per tube for flow cytometry staining. For detection, the samples were
1142 divided into two groups. First, the cells were incubated with anti-mouse CD45 antibody at 4°C in
1143 the dark for 10 minutes. Group 1 was then stained with anti-mouse CD3, CD4, CD8, B220
1144 antibodies, and corresponding isotype control antibodies. Group 2 was stained with anti-mouse
1145 CD45, CD4, CD8, CD44, CD62L antibodies, and corresponding isotype control antibodies.
1146 Intracellular staining for CCR7 and LCK was performed using the eBioscience transcription
1147 factor buffer set from Invitrogen. After incubating at 4°C in the dark for 30 minutes, the cells
1148 were washed once with 1× PBS and analyzed by flow cytometry. The immunophenotyping of
1149 the cells was defined as follows: CD4⁺ T cells (CD45⁺ CD3⁺ CD4⁺), CD8⁺ T cells (CD45⁺
1150 CD3⁺ CD8⁺), B cells (CD45⁺ B220⁺), and CD4⁺ Naive T cells (CD4⁺ CD62L⁺ CD44⁻). Flow
1151 cytometry data were analyzed using FlowJo-V10 software. The number of infiltrating cells per
1152 unit volume of the tumor was calculated as the number of each cell subset divided by the tumor
1153 volume.

1154 **Immunofluorescence and image quantification**

1155 The method for multiplex immunofluorescence staining of paraffin sections was referenced from
1156 our previously published literature⁷⁴. Briefly, tissues were harvested, fixed, and paraffin
1157 embedded. Slides were stained for P16 (Abcam, ab185620, 1:500), P21 (Abcam, ab109520,
1158 1:1000), CD4 (Abcam, ab133616, 1:1000), CD8a (Cell signaling Technology, 70306S, 1:500),
1159 CCR7 (Abcam, ab253187, 1:1000), PAN-CK (Cell signaling Technology, 4545S, 1:2000), LCK
1160 (Cell signaling Technology, 2984S), CD62L (Invitrogen, PA5-95721, 1:500) and S100A11
1161 (Abcam, ab180593, 1:1000) antibodies. Quantification of immune infiltration was done using
1162 QuPath, an open-source software for digital pathology image analysis. For the quantification, at
1163 least three regions of interest (ROI) were selected for each condition and the percentage of
1164 positive cells was calculated.

1165

1166 **Data availability**

1167 All data associated with this study are present in the paper or the Supplementary Materials. The
1168 raw sequence data including single-cell sequencing, TCR/BCR sequencing of human, as well as
1169 RNA and ATAC sequencing of CD4 naïve T cells datasets generated and analyzed during the
1170 current study have been deposited in Genome Sequence Archive (Genomics, Proteomics &
1171 Bioinformatics 2021) with accession code **PRJCA027702 and PRJCA028161**.

1172

1173 **Code availability**


1174 No unique code was used in the study. All relevant references are included in Methods.

1175

1176 **Methods References**

- 1177 65. Nolan, S. *et al.* A large-scale database of T-cell receptor beta (TCR β) sequences and binding associations
1178 from natural and synthetic exposure to SARS-CoV-2. Preprint at <https://doi.org/10.21203/rs.3.rs-51964/v1> (2020).
- 1179 66. Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis.
1180 *Genome Biol* **19**, 15 (2018).
- 1181 67. Polański, K. *et al.* BBKNN: fast batch alignment of single cell transcriptomes. *Bioinformatics* **36**, 964–965
1182 (2020).
- 1183 68. Traag, V. A., Waltman, L. & Van Eck, N. J. From Louvain to Leiden: guaranteeing well-connected
1184 communities. *Sci Rep* **9**, 5233 (2019).
- 1185 69. Huang, Z. *et al.* Effects of sex and aging on the immune cell landscape as assessed by single-cell
1186 transcriptomic analysis. *Proc. Natl. Acad. Sci. U.S.A.* **118**, e2023216118 (2021).
- 1187 70. Zou, Z. *et al.* A Single-Cell Transcriptomic Atlas of Human Skin Aging. *Developmental Cell* **56**, 383-
1188 397.e8 (2021).
- 1189 71. Wang, S. *et al.* A single-cell transcriptomic landscape of the lungs of patients with COVID-19. *Nat Cell*
1190 *Biol* **23**, 1314–1328 (2021).
- 1191 72. Zheng, Y. *et al.* A human circulating immune cell landscape in aging and COVID-19. *Protein Cell* **11**,
1192 740–770 (2020).
- 1193 73. Subramanian, A. *et al.* Gene set enrichment analysis: A knowledge-based approach for interpreting
1194 genome-wide expression profiles. *Proc. Natl. Acad. Sci. U.S.A.* **102**, 15545–15550 (2005).
- 1195 74. Peng, Y. *et al.* Single-cell profiling of tumor-infiltrating TCF1/TCF7⁺ T cells reveals a T lymphocyte
1196 subset associated with tertiary lymphoid structures/organs and a superior prognosis in oral cancer. *Oral Oncol* **119**,
1197 105348 (2021).
- 1198

Fig. 1






Fig. 3




Fig. 4




Fig. 5




Fig. 6

